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1 Summary
The majority of excitatory transmission in the brain is mediated by glutamatergic synapses.
Rapid synaptic signaling is mediated by AMPA and kainate receptors, whereas NMDA recep-
tors mediate slow synaptic currents. Pathophysiological activation of glutamatergic neurons
can lead to excitotoxicity and neuronal death, for example in ischaemia and neurodegen-
erative disorders. Therefore, studying the structure and function of AMPA receptors is
important for understanding general mechanisms of synaptic transmission as well as for the
development of new therapies.
AMPA receptors are associated with auxiliary subunits called Transmembrane AMPA
Receptor Regulatory Proteins (TARPs). The first identified member of this family was
stargazin. Given the structural similarity to the γ1 subunit of skeletal muscle voltage-gated
Ca2+-channels, stargazin is also called γ2. The stargazer mouse is a spontaneous mutant
that lacks AMPA receptors in granule cells of cerebellum and suffer from ataxia. In addition
to stargazin, the family includes γ3, γ4 and γ8. TARPs regulate all aspects of AMPA
receptor function - from early steps of synthesis and trafficking to the cell surface, to synaptic
localization and biophysical properties. TARPs interact with PSD-95, a main scaffolding
protein of excitatory synapses that belongs to the Membrane-Associated Guanylate Kinases
(MAGUK) family. Via this interaction AMPA receptors are localized to the synapse. PSD-95
clusters many other synaptic proteins and organizes signaling complexes in the synapse.
The goal of this thesis was to investigate the role of stargazin in regulating the antagonism
of AMPA receptors. I focused on the commonly used antagonists CNQX, GYKI-53655
(GYKI) and CP-465,022 (CP) and explored how stargazin changes the inhibition of AMPA
receptors by these drugs. The second goal was to assess the role of PSD-95 in synaptic
function. More specifically, I aimed to investigate how an increased level of PSD-95 in a
neuron affects AMPA and NMDA currents, as well as the presynaptic function of a neuron.
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In the first part of my thesis I used the heterologous Xenopus oocyte expression system to
express AMPA receptor subunits alone or with stargazin. Using the two-electrode voltage
clamp, I measured the glutamate-evoked currents and obtained dose-response curves for
CNQX, GYKI and CP. I found that stargazin decreases the affinity of GluR1 for CNQX,
which was explained by the partial agonistic effect of CNQX in the presence of stargazin.
In contrast, stargazin increases the affinity for GYKI, and has only a small effect on CP.
I also tested the effect of stargazin on recently described GYKI-insensitive receptors and
found that inhibition of these receptors is restored by co-expression with stargazin. My
data strongly suggest that the identified residues do not constitute the full GYKI-binding
site. I could also show that the ectodomain of stargazin controls the changes in antagonist
sensitivity of the receptors.
In the second part of my thesis I used cultured hippocampal slices and Semliki Forest virus
to overexpress PSD-95:GFP in CA1 region of hippocampus. I recorded simultaneously from
a cell overexpressing PSD-95 and a neighboring control cell and compared their AMPA and
NMDA currents. I confirmed the finding that overexpression of PSD-95 robustly increases
currents mediated by AMPA receptors. In contrast to other studies, I observed that PSD-95
increases NMDA currents, although to smaller extent. I addressed the debated role of PSD-95
in regulating the presynatic release probability and found that overexpression of PSD-95 did
not change glutamate release probability. Importantly, I observed that cells overexpressing
PSD-95 have a lower rectification index of synaptic AMPA receptors, strongly suggesting
that PSD-95 overexpression led to an increased fraction of AMPA receptors that lack GluR2
subunit.
In conclusion, the work presented in this thesis gives further insights into AMPA receptor
physiology, both from the aspect of pharmacology and synaptic trafficking. The results of
co-expression of stargazin with the previously described GYKI-insensitive GluR1 mutants
strongly indicate that TARP interacts with the linker domains of AMPA receptors. This
finding is of great importance for understanding the molecular mechanism of AMPA-TARP
interaction. Furthermore, this thesis shows that PSD-95 regulates both AMPA and NMDA
synaptic currents by increasing the number of synaptic receptors. In addition, my data
suggest that PSD-95 enriches the number of GluR2-lacking receptors in the synapse. Given
the Ca2+-permeability of GluR2-lacking receptors and their implication in plasticity and
2
excitotoxicity, this finding is important for understanding how the synaptic localization of
these receptors is regulated.
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2 Abbreviations
2-ClAd 2-chloroadenosine
ABP AMPA receptor-binding protein
ACSF artificial cerebro-spinal fluid
APV amino-5-phosphonopentanoate
AMPA α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
AMPA-R AMPA receptor
BHK baby hamster kidney
CA1 Cornu ammonis 1
CA3 Cornu ammonis 3
Cdk5 Cyclin-dependent kinase 5
CI Ca2+-impermeable
CNQX 6-cyano-7-nitroquinoxaline-2,3-dione
CNS central nervous system
CP Ca2+-permeable
CP-465,022 3-(2-chloro-phenyl)-2-[2-(6-diethylaminomethyl-pyridin-2-yl)
-vinyl]-6-fluoro-3H-quinazolin-4-one
CTZ cyclothiazide
DIV days in vitro
DMSO dimethyl sufoxide
DNQX 6,7-dinitroquinoxaline-2,3-dione
EPSC excitatory postsynaptic current
GFP green fluorescent protein
GK guanylate kinase
GRIP glutamate receptor-interacting protein
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2 Abbreviations
GYKI-53655 1-(4-aminophyl)-4-methyl-7,8-methylendioxy-5H-2,3-benzodiazepine
LBD ligand-binding domain
LTD long-term depression
LTP long-term potentiation
MAGUK membrane-associated guanylate kinase
NBQX 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide
NMDA N-methyl-D-aspartate
NMDA-R NMDA receptor
NSF N-ethylmaleimide-sensitive factor
PDZ PSD95/disc large/zona occludens 1
PEPA 4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluorophenoxyacetamide
PICK1 protein interacting with C-kinase
PSD postsynaptic density
PSD-93 postsynaptic density protein of 93 kDa
PSD-95 postsynaptic density protein of 95 kDa
SAP102 synapse-associated protein of 102 kDa
SAP97 synapse-associated protein of 97 kDa
SFV Semliki Forest Virus
SH3 Src-homology 3
Stg stargazin
TARP transmembrane AMPA receptor regulatory proteins
TCM trichlormethiazide
TEVC two-electrode voltage clamp
TTX tetrodotoxin
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3 Introduction
The majority of excitatory synapses in the central nervous system (CNS) is glutamater-
gic. Glutamate acts on two classes of glutamate receptors: ionotropic and metabotropic.
Ionotropic receptors are ligand-gated ion channels, whereas metabotropic receptors act by ac-
tivating a second messenger cascade. The focus of this study will be on the ionotropic recep-
tors. Ionotropic glutamate receptors are divided into three subfamilies: AMPA (α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate), NMDA (N-methyl-D-aspartate) and kainate re-
ceptors. All three receptor subfamilies are cation-channels, selective for Na+ and K+. Sub-
population of AMPA receptors, as well as all NMDA and kainate receptors are also permeable
for Ca2+. Rapid synaptic transmission is mediated by AMPA and kainate receptors. In con-
trast, NMDA receptors mediate slow synaptic currents and they are involved in initiation of
some forms of synaptic plasticity. AMPA and NMDA receptors are discussed in more details
in the following sections. Kainate receptors mediate synaptic responses only in some brain
regions and they are not in the scope of this study.
This study is an effort to understand both the regulation of AMPA receptor biophysical
properties and synaptic localization. Under normal physiological conditions the strength of a
glutamatergic synapse is modulated to adapt to local or global changes in neuronal activity.
This ”plasticity” of the synapses can be expressed as a change in the receptor number and
also receptor properties. In addition, pathophysiological activation of glutamatergic neurons
can lead to a large increase in intracellular Ca2+, excitotoxicity and neuronal death, for
example in ischaemia and neurodegenerative disorders. Taken together, there is growing
interest in understanding the AMPA receptor pharmacology.
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3.1 Excitatory synapses
Chemical synapses are functional connections between neurons. The information is passed
uni-directionally from a presynaptic cell to a postsynaptic cell and therefore the chemical
synapses are asymmetric in structure and function. The presynaptic terminal, or synap-
tic bouton, is a specialized area within the axon that contains synaptic vesicles filled with
neurotransmitter. Juxtaposed to the presynapse is a region of the postsynaptic cell con-
taining neurotransmitter receptors. In excitatory synapses the receptors are often found in
specialized protrusions from the dendrites called dendritic spines.
Figure 3.1: Mammalian excitatory synapse with a focus on the postsynaptic side. Cytoplasmic
C-terminal tails of proteins are indicated by black lines. Adopted from (Kim and Sheng, 2004).
An excitatory synapse is a synapse in which an action potential in the presynaptic cell
increases the probability of an action potential occurring in the postsynaptic cell. Activation
of the postsynaptic receptors generates excitatory postsynaptic currents (EPSCs), a depo-
larization of the postsynaptic membrane caused by the flow of positively charged ions into
8
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the cell.
A scheme of a glutamatergic synapse is given in figure 3.1, illustrating the complexity of
proteins that take part in synaptic function. AMPA and NMDA receptors are localized in
the postsynaptic membrane and they mediate glutamate binding. AMPA receptors have
associated auxiliary subunits, transmembrane proteins of the TARP family with stargazin
being the first member identified. TARPs are discussed in more details in a following sec-
tion. Beside AMPA and NMDA receptors, other channels and transmembrane proteins are
localized in the postsynaptic membrane that are involved in different aspects of regulation
of synaptic function.
On the intracellular side of the postsynaptic membrane is a complex of interlinked pro-
teins called the postsynaptic density (PSD). Proteins of the PSD are involved in trafficking
and localization of synaptic receptors and also in organizing the postsynaptic signaling path-
ways. They are cytoplasmic proteins often containing multiple PDZ (PSD95/disc large/zona
occludens 1) domains. The main scaffolding protein of the excitatory synapses is PSD-95.
PSD-95 is a PDZ protein that belongs to the MAGUK family, which is the subject of another
section of the Introduction.
3.2 AMPA receptors
Structure. AMPA receptors are tetrameric complexes composed of four different subunits,
GluR1-4 (Hollmann and Heinemann, 1994). Each subunit has three transmembrane do-
mains and one re-entrant loop (Fig. 3.3A). These loops form the pore of the receptor. The
extracellular domains of the receptor form a ligand-binding domain (LBD), a clamshell-like
structure containing the glutamate binding sites.
AMPA receptor subunits are alternatively spliced in a region preceding the fourth mem-
brane domain, giving flip and flop splice variants of each subunit (Sommer et al., 1990).
This region regulates some of the receptor properties, e.g. the flop versions desensitize and
deactivate more rapidly than the flip versions (Mosbacher et al., 1994). Flip and flop splice
variants affect also AMPA receptor trafficking, with flop isoforms being largely retained in
endoplasmic reticulum (Coleman et al., 2006). These two splice variants are differentially
expressed. Adult pyramidal CA1 neurons of hippocampus express mainly flop variants,
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whereas flip isoforms dominate prior to birth (Monyer et al., 1991).
An interesting finding followed the AMPA receptor subunits cloning: the genomic GluR2
subunit sequence was different from the GluR2 cDNA sequence in a single amino acid in the
pore region (Sommer et al., 1991). Namely, the GluR2 subunit is edited on RNA level in the
pore domain: glutamine at position 607 is edited into arginine (Q/R editing site). All the
other subunits have unchanged glutamine at this position. Edited GluR2 subunits are largely
unassembled and retained in endoplasmatic reticulum, whereas GluR1 and GluR2Q subunits
readily tetramerize (Greger et al., 2002; Greger et al., 2003). These effects on tetramerization
and retention in the ER ensure that GluR2 subunit is available for co-assembly with other
subunits.
+ 40 mV
- 60 mV
+ 40 mV
- 60 mV
Non-rectifying AMPA receptors
Rectifying AMPA receptors
I (norm)
V (mV)-80 -60 -40 -20 20 40
-1.5
-1.0
-0.5
0.5
1.0
Non-Rectifying
Rectifying
Figure 3.2: Traces of mean evoked AMPA currents recorded at -60 mV and +40 mV mediated
by rectifying and non-rectifying AMPA receptors (left). Scale bars: 40 pA, 25 ms. The current
traces are taken from (Steiner et al., 2005). I-V curve of rectifying receptors show smaller
currents at positive voltages compared to non-rectifying receptors (right).
RNA editing of GluR2 has a large impact on AMPA receptor function. The presence of
edited GluR2 subunit controls the biophysical properties of the receptors, such as Ca2+-
impermeability and linear current-voltage (I-V) curve. GluR2-lacking receptors are Ca2+-
permeable, have high single-channel conductance and are blocked by endogenous polyamines
at positive voltages and therefore exhibiting inwardly rectifying I-V relationship. The exam-
ple of I-V curves of GluR2-containing (non-rectifying) and Glu2-lacking (rectifying) receptors
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are shown in figure 3.2. Rectifying receptors allow only small outward current due to the
polyamine block at positive voltages.
AMPA receptors can be subdivided into two groups based on their cytoplasmic tail: GluR2
and GluR3 have short cytoplasmic domain whereas GluR1 and GluR4 have long cytoplasmic
domain. The C-terminus of each subunit interacts with specific cytoplasmic proteins, many
of which are proteins with multiple PDZ domains. For example, GluR1 interacts with
SAP97 (synapse-associated protein of 97 kDa), the only member of MAGUK family shown
to interact directly with AMPA receptors (Leonard et al., 1998). GluR2 and GluR3 interact
with GRIP (glutamate receptor-interacting protein), ABP (AMPA receptor-binding protein)
and PICK1 (protein interacting with C-kinase). In addition to the PDZ proteins, cytoplasmic
tail of GluR2 interacts with NSF (N-ethylmaleimide-sensitive factor), a protein involved in
vesicles exocytosis. These interactions of AMPA receptor subunits play important roles in
controlling their trafficking and stabilization at the synapse.
In the adult hippocampus, two populations of AMPA receptors predominate: receptors
composed of GluR1/GluR2 and GluR2/GluR3 (Wenthold et al., 1996). Although the ma-
jority of AMPA receptors in the CNS are GluR2-containing, significant expression of GluR2-
lacking receptors in various brain regions has been observed. Since GluR2-lacking receptors
are Ca2+-permeable, they have been implicated in the processes of synaptic plasticity and
excitotoxicity.
Gating. AMPA receptors are activated upon agonist binding to the LBD, which includes
two polypeptide segments, D1 and D2 (Fig. 3.3B). Glutamate binding leads to the rotation
of the D2 domain towards the D1 by ≈ 21◦ and closure of the ”clamshell”-like structure.
This conformational change leads to the channel pore opening (Armstrong and Gouaux,
2000). Beside glutamate which acts as a full agonist on AMPA receptors, there are also
partial agonists of AMPA receptors. For example, kainate binds to the LBD but only leads
to a partial opening of the pore. Deactivation is a process opposite to the activation: the
clamshell re-opens, pore closes and glutamate is released from the LBD.
Receptors are in the open-state only briefly given that closed clamshell is a high energy
conformation. Therefore the receptors are rapidly desensitized. Desensitization is a con-
formational change of a receptor that leads to the pore closure in the continued presence
of glutamate. It involves a ≈ 14◦ rotation of D1 toward D2 that leads to the pore closure
11
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Q/R
D1 - D2
A B
Figure 3.3: A, Schematic diagram of AMPA receptor subunit. Depicted are N- and C- terminal
domain (NTD and CTD), ligand-binding domain (LBD) with segments D1 and D2, flip/flop
splicing region and Q/R editing site. Modified from (Ziff, 2007). B, Two subunits of AMPA
receptor tetramer with their D1 and D2 domains. Binding of glutamate (yellow circles) to the
receptor is followed by a conformational change leading to open and desensitized state. Modified
from (Armstrong et al., 2006).
(Armstrong et al., 2006). Conformation of desensitized receptors is very stable and receptors
have large preference for this state.
AMPA receptors and synaptic plasticity. Postsynaptic changes in AMPA receptor
function are an important contribution to the expression of long-term potentiation (LTP) and
long-term depression (LTD), cellular correlates of learning and memory. The main feature
of LTP and LTD is that a short period of synaptic activity can trigger persistent changes
of synaptic transmission lasting at least several hours. The main question in understanding
the mechanism of synaptic plasticity is whether the changes in synaptic strength originate
from the postsynaptic or the presynaptic modification. The answer to this question was
the identification of postsynaptically ”silent synapses”. These synapses contain only NMDA
receptors and upon LTP they can be converted into active synapses through a recruitment
of AMPA receptors (Malinow and Malenka, 2002). Several studies showed using different
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techniques that GluR1-containing receptors were delivered into synapses upon LTP induction
(Shi et al., 1999; Hayashi et al., 2000; Kakegawa et al., 2004). On the other hand, removal
of GluR2-containing AMPA receptors from the synapses underlies LTD.
How does the AMPA receptor number change during synaptic plasticity? Both receptor
endo/exocytosis and lateral diffusion in the membrane seem to be involved. The favored
model is that AMPA receptors do not directly exchange between the PSD and cytosolic
compartments. Instead, exocytosis and endocytosis occur at extrasynaptic membrane sites
from which AMPA receptors laterally diffuse into or out of the synapse.
Another evidence that activity influences the number of synaptic AMPA receptors comes
from experiments with chronic pharmacological manipulations of network activity. Increas-
ing network activity causes decrease in synaptic AMPA receptor number, while chronic
application of AMPA receptor antagonists causes the receptor number increase (Turrigiano
and Nelson, 1998; O’Brien et al., 1998). These are the processes of homeostatic synaptic
scaling, a form of synaptic plasticity that scale the strength of all of a neuron excitatory
synapses up or down to stabilize neuronal firing.
3.3 Pharmacology of AMPA receptors
Agonists. The binding of an agonist to AMPA receptor leads to a conformational change of
the LBD that spreads to the membrane spanning domains to open the channel. Glutamate
is a full agonist of AMPA receptors and its binding to the receptor leads to the complete
conformational change of the LBD. Besides glutamate, AMPA and quisqualate also act as
full agonist of AMPA receptors. Kainate and propionic acid are partial AMPA receptor
agonists and they lead to the incomplete conformational change of the LBD and therefore
partial opening of the pore. AMPA has a high selectivity for AMPA receptors over kainate
receptors (10-20 fold higher affinity for GluR1-4 over a GluR5 kainate subunit), whereas
kainate shows high selectivity for kainate receptors. AMPA receptors mediate rapidly de-
sensitizing responses to AMPA, quisqualate and glutamate, but non-desensitizing responses
to kainate. The structure of AMPA and glutamate are shown in figure 3.4.
Antagonists. Two classes of antagonists act on AMPA receptors: competitive and non-
competitive. Competitive antagonists bind to AMPA receptors in the same binding pocket
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Figure 3.4: Structures of AMPA receptor agonists: AMPA and glutamate, antagonists: GYKI,
CP and CNQX, and positive modulator TCM.
as agonists, thereby occluding agonist binding. On the other hand, non-competitive antagon-
sits (also termed negative modulators or allosteric antagonists) bind outside of the agonist
binding site and interfere with the conformational change that leads to the channel opening.
The quinoxalinediones family of the competitive AMPA and kainate receptor antagonist
was first developed. The family consists of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX),
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6,7-dinitroquinoxaline-2,3-dione (DNQX), and 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]-
quinoxaline-7-sulfonamide (NBQX). However, given the recent finding that CNQX and
DNQX can act also as partial agonists on AMPA receptors (Menuz et al., 2007), as well
as their poor pharmaceutical properties in clinical development, there has been a need for
developing new antagonists.
Changing the position of the nitrogen atoms in the structure of 1,4-benzodiazepines led to
the discovery of a 2,3-benzodiazepines, a family of non-competitive AMPA receptor antago-
nists. The 2,3-benzodiazepine derivative GYKI-52466 was first found to exhibit anticonvul-
sant potency and neuroprotection (Tarnawa et al., 1989). Later more selective and potent
analogs have been developed by the substitution at the N-3 position, e.g. GYKI-53655 (1-
(4-aminophyl)-4-methyl-7,8-methylendioxy-5H-2,3-benzodiazepine, Fig. 3.4). GYKI-53655
has the advantage of being a selective antagonist for AMPA receptors over kainate receptors
and more potent than GYKI-52466.
Another non-competitive AMPA receptor antagonist, CP-465,022 (3-(2-chloro-phenyl)-
2-[2-(6-diethylaminomethyl-pyridin-2-yl)-vinyl]-6-fluoro-3H-quinazolin-4-one, Fig. 3.4) was
developed from the efforts to increase the potency and selectivity of previously known piri-
qualone. CP-465,022 is an AMPA receptor selective derivative of piraquilone and is about
100-fold more potent on AMPA receptors than GYKI-53655.
Positive modulators. AMPA receptor-mediated synaptic currents are very brief (1-2
ms) because of the rapid inactivation of AMPA receptors by the processes of deactivation
and desensitization. There is a class of drugs that block desensitization and slow deactivation
of AMPA receptors, therefore promoting excitatory transmission. They are also called posi-
tive allosteric modulators and are typified by cyclothiazide (CTZ) and trichlormethiazide
(TCM). The structure of TCM is shown in figure 3.4. CTZ and TCM bind within LBD
and stabilize the dimer interface. CTZ shows a preference for the flip variants of AMPA
receptors (Partin et al., 1996), whereas the potentiator 4-[2-(phenylsulfonylamino)ethylthio]-
2,6-difluorophenoxyacetamide (PEPA) acts specifically on flop isoforms (Sekiguchi et al.,
1997).
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3.4 Transmembrane AMPA receptor regulatory proteins (TARPs)
Until recently trafficking of AMPA receptors was thought to be regulated solely by the
interactions of their C-termini with proteins like PICK1, GRIP, SAP97 and others. The fact
that PSD-95, a scaffolding protein that clusters synaptic proteins, does not interact directly
with AMPA receptor subunits implied the existence of some link-protein between AMPA
receptor and PSD-95. Stargazin was found to be that link protein.
The stargazer mouse is a spontaneous mutant that shows characteristic behavior of fre-
quently tipping its head back to stare upward (Noebels et al., 1990). These mice suffer
from epileptic discharges in the neocortex and ataxic gait (Noebels et al., 1990). The gene
disrupted in stargazer mice, Cacng2, encodes a 36-kD protein, stargazin, with structural
similarity to the γ1 subunit of skeletal muscle voltage-gated Ca2+-channels and it is also
called γ2 (Letts et al., 1998). Stargazer mice lack AMPA receptors in cerebellar mossy
fiber to granule cell synapses, indicating a role of stargazin in synaptic targeting of AMPA
receptors (Chen et al., 2000).
The TARP family consists of stargazin and stargazin-related proteins with a role in regu-
lating AMPA receptors, including γ3, γ4 and γ8 (Tomita et al., 2003) (Fig. 3.5B). TARPs
are members of a large superfamily of four pass transmembrane proteins that include the
γ1 subunit of the skeletal muscle calcium channel and claudin family tight junction proteins
(Fig. 3.5A). Proteins in the TARP family share 60 % sequence homology and are differen-
tially expressed in the brain, γ2 being preferentally expressed in the cerebellum, γ3 in the
cortex, γ4 in scattered cells in white matter of cerebellum and corpus callosum and γ8 in
the hippocampus (Tomita et al., 2003).
A family of type II TARPs has been recently described, comprising of γ5 and γ7 (Kato
et al., 2008). γ5 modulates only receptors containing edited GluR2 subunit and regulates
channel properties in a different way from canonical TARPs: it increases rates of GluR2
deactivation and desensitization and decreases glutamate potency, with no effect on receptors
trafficking (Kato et al., 2008).
As auxiliary subunits of AMPA receptors, TARPs control both the receptor trafficking and
channel properties of AMPA receptors. Distinct domains of stargazin are involved in these
function: the C-terminal tail regulates trafficking of AMPA receptors whereas ectodomain of
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Figure 3.5: A, Scheme of stargazin structure. Depicted are cytoplasmic N- and C- terminus
and the first ectodomain that modulates biophysical properties of AMPA receptors. The PDZ
domain at the very end of the C-terminus intracts with PSD-95. B, Phylogenetic tree of TARPs
and related proteins. Adopted from (Tomita et al., 2003).
stargazin controls biophysical properties of AMPA receptors (Tomita et al., 2005). Stargazin
delivers AMPA receptors to the cell surface and regulates receptor synaptic localization
through an interaction with PSD-95 (Chen et al., 2000). It slows AMPA receptor activation,
deactivation and desensitization and increases the efficacy of partial agonist kainate (Tomita
et al., 2005; Priel et al., 2005; Turetsky et al., 2005). In addition, stargazin increases the
efficacy of CTZ on AMPA receptors (Tomita et al., 2006) and attenuates the rectification of
AMPA receptors (Soto et al., 2007).
It seems that all AMPA receptors are associated with TARPs, given the current lack of
evidence for ”TARP-less” receptors. However, many aspects of the AMPA receptor-TARP
interaction are not fully understood. The interacting sites of both TARP and AMPA receptor
are not identified yet. Furthermore, the number of TARP molecules per AMPA receptor
tetramer is not known, as well as whether this number is constant or dynamically regulated.
Whether TARP binding is AMPA receptor subunit-dependent is yet another mystery.
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3.5 NMDA receptors
NMDA receptors contribute to the excitatory synaptic transmission and have a critical role
in synaptic plasticity. They have some unique functional features, which include block by
extracellular Mg2+ at negative voltages, high permeability to Ca2+ and slow current kinetics.
NMDA receptors are released from the Mg2+-block during membrane depolarization that
is mediated by activation of AMPA receptors. The synapses with only NMDA receptors
are referred as ”silent”. Ca2+ influx trough NMDA receptors can lead to different forms
of NMDA receptor-dependent synaptic plasticity. Depending on the pattern of synaptic
stimulation, synapses can undergo LTP or LTD.
Gating of NMDA receptors is modulated by several ligands and modulators: the co-agonist
glycin must bind in addition to glutamate for the channel to open. Extracellular Zn2+ and
polyamines also modify the behavior of the receptor.
NMDA receptors are tetramers composed of three subunit types, NR1, NR2(A-D) and
NR3. In the hippocampus, the NR1 subunit can assemble as heterodimers containing
NR1/NR2A or NR1/NR2B or as heterotrimers containing NR1/NR2A/NR2B. NR2B-con-
taining NMDA receptors are expressed early in development, while the expression of NR2A-
containing receptors increases during development (Monyer et al., 1994). Importantly,
NR2B-containing receptors have a slower decay compared to NR2A-containing receptors.
The glycine-binding site is located in NR1 subunit, whereas NR2 binds glutamate.
NMDA receptor subunits interact with various intracellular scaffolding and signaling
molecules within postsynaptic density, for example PSD-95, S-SCAM and CIPP (Cantallops
and Cline, 2000). However, their trafficking to the cell surface and regulation of their synap-
tic localization is not well establish. Their mobility in the membrane is generally smaller
than of AMPA receptors and changes in neuronal activity affect mainly AMPA receptor
but not NMDA receptor mobility (Groc et al., 2004). However, the subunit composition of
synaptic NMDA receptors can quickly change in an activity-dependent manner in neonatal
synapses, which is thought to regulate the requirement for evoking LTP or LTD (Bellone
and Nicoll, 2007).
Inappropriate activation of NMDA receptors is implicated in several diseases. In partic-
ular, excessive Ca2+ influx through NMDA receptors can cause excitotoxic neuronal death.
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Therefore NMDA receptors are potential therapeutic targets for treating stroke and seizures.
3.6 Membrane-associated guanylate kinases (MAGUKs)
MAGUK proteins have been shown by genetic, electrophysiological and morphological stud-
ies to be essential for controlling the structure, strength and plasticity of glutamatergic
synapses. Modifications of MAGUK protein function in the glutamatergic synapse has been
already described in several neurological disorders such as Alzheimer’s disease, Parkinson’s
disease, Huntington’s disease, ischemia, schizophrenia and neuropathic pain, reviewed by
(Gardoni, 2008).
MAGUKs comprise a family of scaffolding molecules at excitatory synapses. The proto-
typical member of the family is postsynaptic density protein of 95 kDa, PSD-95. The family
includes also PSD-93, SAP-102 and SAP-97 (Funke et al., 2005). All MAGUKs share a com-
mon domain structure organization with three N-terminal PDZ domains, a Src-homology 3
(SH3) domain and C-terminal catalytically inactive guanylate kinase (GK) domain (Fig.
3.6). The N-terminal region of PSD-95 and PSD-93 contains two cysteines that undergo
palmitoylation, whereas SAP-97 contains the L27 domain instead.
MAGUK proteins are expressed in all regions of the brain, but their relative abundance
changes during development. SAP102 is expressed in the hippocampus in the early postnatal
period and decreases with age, whereas PSD-95 and PSD-93 expression increases by one
month of age (Sans et al., 2000).
PSD-95 is located in the postsynaptic density in close proximity to the postsynaptic mem-
brane. Given its location and multiple PDZ domains it has potential of clustering synaptic
receptors and channels. PSD-95 interacts with AMPA receptors via TARPs, and directly
with NR2 subunit of NMDA receptors and K+ channel. Beside clustering and stabiliza-
tion of the receptors at the synapse, PSD-95 modulates the activity of the proteins it binds
to. For example, it reduces single-channel conductance of the inward-rectifying K+ chan-
nel (Nehring et al., 2000) and regulates NMDA receptor desensitization (Sornarajah et al.,
2008). Another important role of PSD-95 is to organize signaling complexes at the PSD.
For instance PSD-95 interacts with neuronal nitric oxide synthase (nNOS), an enzyme that
produces nitric oxide implicated in retrograde signaling in synapses. Also, PSD-95 binds to
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Figure 3.6: Members of MAGUK family: PSD-95, PSD-93, SAP102 and SAP97 with their
PDZ, SH3 and GK domains. SAP97 contains L27 domain in its N-terminus.
kalirin-7, a protein involved in spine formation (Penzes et al., 2001).
Synaptic abundance of PSD-95 is regulated by neuronal activity. Neuronal activity pro-
motes the dispersal of PSD-95 from the synapses by depalmitoylation of PSD-95 N-terminus
(El-Husseini Ael et al., 2002) and also through the ubiquitin-proteasome pathway (Colledge
et al., 2003). The function of PSD-95 is also regulated by phosphorylation. CamKII phos-
phorylates PSD-95 at Ser73 that destabilizes PSD-95 in the PSD (Steiner et al., 2008).
It seems that phosphorylation of PSD-95 by CamKII is not important for basal synaptic
transmission mediated by AMPA and NMDA receptors, but for spine growth and LTP ex-
pression. Phosphorylation of another serine in PSD-95, Ser295, is important for the synaptic
accumulation of PSD-95. This phosphorylation is mediated by Rac1-JNK1 signaling path-
way and enhances synaptic accumulation of PSD-95 and the ability of PSD-95 to recruit
AMPA receptors to the synapse (Kim et al., 2007). Cyclin-dependent kinase 5 (Cdk5) phos-
phorylates N-terminal domain of PSD-95 and inhibits its multimerization (Morabito et al.,
2004). Cdk5-dependent phosphorylation of PSD-95 was proposed to dynamically regulate
the clustering of PSD-95/NMDA receptor complexes at the synapse.
As the main component of the excitatory PSD, PSD-95 has been studied by many labs.
The main findings are reviewed by (Elias and Nicoll, 2007). The conclusion that emerged
from these studies is that PSD-95 regulates the number of synaptic AMPA receptors, whereas
the number of synaptic NMDA receptors seems not to depend on PSD-95. The possible role
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of PSD-95 in presynaptic neurotransmitter release is not well established in the field. There
are still many open questions regarding the roles of PSD-95 in the synapse and how different
mechanisms orchestrate together to control the abundance of different MAGUKs at the
synapse.
3.7 Hipppocampal preparation
The hippocampus is located inside the medial temporal lobe of the cerebral cortex. It
belongs to the limbic system and plays a major role in memory and spatial navigation.
The hippocampus came in the focus of neuroscience when Scoville and Milner published
the study on H.M., a patient who had his two hippocampi surgically removed for treatment
of epilepsy. The patient had severe memory deficits (Scoville and Milner, 1957). Since
that finding, hippocampus became the favorite brain region to study neuronal plasticity, a
cellular correlate of memory. This led to the discovery of ”place cells”, hippocampal neurons
that are activated selectively when an animal moves through a particular location in space
(O’Keefe and Dostrovsky, 1971). Therefore the hippocampus has been proposed to function
as a spatial map of the brain.
The hippocampus has the shape of a curved tube, named a ram’s horn (Cornu Ammonis).
Pyramidal cells, principal cell of the hippocampus, account for 85-90% of the total cell
number. There are also various interneurons identified in the hippocampus, but their number
is small compared to the pyramidal cells. The CA3 and CA1 (Cornu ammonis 3 and 1)
regions of hippocampus contain populations of pyramidal cells that are similar in many
aspects but they differ in some of their physiological properties and connectivity (Fig. 3.7).
CA3 cells receive inputs from the granule cells of the dentate gyrus. This synapse is also
called mossy fiber synapse due to the numerous and large presynaptic terminals. Dentate
gyrus is a region of adult neurogenesis. Neuronal stems cells proliferate and produce new
cells which are important for normal learning and memory and their dysfunction is involved
in some diseases. Pyramidal neurons of CA3 region project their axons, also called Schaffer
collaterals, to CA1 pyramidal cells and also other CA3 cells (Fig. 3.7).
Given its anatomical features, e.g. laminal structure and simple connectivity pattern,
hippocampus has been used to study synaptic plasticity, seizure activity and ischemia. The
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Figure 3.7: Neuronal organization in a hippocampal slice. CA3 and CA1 regions are depicted
as well as Schaffer collaterals pathway. Granule cell from dentate gyrus project their mossy
fibers to the CA3 region. Modified from Cajal, 1911.
Schaffer collateral-CA1 synapse has been a favorite model synapse to study basal synaptic
transmission and LTP. The capacity of hippocampal synapses to change with activity comes
from the intrinsic properties of hippocampal neurons, for example high expression level of
NMDA receptors (Malenka and Nicoll, 1993).
Organotypic slice cultures have the main advantage of a fairly intact histotypic organiza-
tion (Stoppini et al., 1991), i.e. hippocampal laminal structure is well preserved. The slices
can be cultured for several weeks and it has been shown that neuronal development in the
slices resembles development in vivo. Cultured hippocampal slices allow for various experi-
mental manipulations. For example, neurons can be cultured under different biochemical
conditions or single cells can be altered using different molecular biology methods.
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3.8 Summary of aims
AMPA receptors mediate the fast component of excitatory transmission in the brain. By now
many aspects of AMPA receptor function, like structure, assembly, trafficking and gating,
have been well understood. A new chapter in AMPA receptor physiology was opened when
it was found that AMPA receptors are associated with auxiliary subunits, named TARPs.
Since that finding the main goal of many studies dealing with the AMPA receptors was to
understand the role of TARPs in AMPA receptor function. It is clear by now that TARPs
are involved in almost every aspect of AMPA receptor function. Importantly, TARPs are
shown to be the link between AMPA receptors and the synaptic scaffolding molecule, PSD-
95. PSD-95 is a member of MAGUK family and has been studied by many laboratories as
a synaptic ”slot” candidate which could determine the number of synaptic receptors and
therefore the synaptic strength.
However, there is still a long list of open questions regarding the TARP-AMPA receptor
interaction and the role of PSD-95 in regulating synaptic transmission. The goal of this
study was to further explore the effect of TARP association on AMPA receptor function,
focusing on stargazin, the prototypical TARP. The second goal was to assess the role of
PSD-95 in the synapse and to understand the origin of some conflicting results obtained in
different laboratories.
In the first part of my thesis, I investigated the effect of stargazin on AMPA receptor
pharmacology. To that end, I employed the Xenopus oocyte heterologous expression system
to study isolated AMPA receptor-mediated currents. I measured dose-response curves of
GluR1 for different AMPA receptor antagonists in the presence and absence of stargazin.
The focus was on commonly used antagonists CNQX, GYKI-53655 and CP-465,022.
In the second part of this study, I explored how PSD-95 regulates synaptic transmission.
I virally overexpressed PSD-95 in cultured hippocampal slices and measured AMPA and
NMDA currents from infected and neighboring control cells. By use of various experimen-
tal paradigms I assessed the presynaptic function, as well as AMPA and NMDA receptor
subunit-composition in cells overexpressing PSD-95.
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4.1 Material
All the chemicals and media used in this study are listed in the following two tables. Chem-
icals were dissolved either in distilled water or dimethyl sufoxide (DMSO).
4.1.1 Chemicals
Chemical Supplier
(+)MK-801 hydrogen maleate Sigma
(2R)-amino-5-phosphonopentanoate (APV) BioTrend
2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-7-
sulfonamide (NBQX)
BioTrend
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris, Trizma
base)
Sigma
2-chloroadenosine Sigma
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) Tocris
6x gel loading buffer Fermentas
Adenosine 5’-triphosphate magnesium salt (MgATP) Sigma
Agarose Inivitrogen
Aprotinin Sigma
Bovine albumin powder Sigma
Calcium chloride dihydrate (CaCl2) Merck
Calcium nitrate tetrahydrate (Ca(NO3)2) Merck
Cesium chloride (CsCl) Sigma
Cesium methane-sulfonate (CsMeSO4) Sigma
Collagenase Type 3 Worthington
CP-465,022 Pfizer
D(+)Glucose monohydrate Merck
Dimethyl sufoxide (DMSO) Merck
Ethidiumbromide Solution Fluka Chemie
Ethyl-3-aminobenzoate methanesulfonate salt Sigma
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Chemical Supplier
Fetal bovine serum Biochrom
Gel Mount I M Aqueous Mounting Medium Sigma
GeneRuler 1kb DNA-ladder Fermentas
Gentamycin Sigma
Glacial acetic acid Merck
Guanosine 5’-triphosphate sodim salt hydrate (NaGTP) Sigma
GYKI-53655 Taros
Horse serum Gibco
L-Glutamic acid sodium salt hydrate Sigma
L-Glutamin Gibco
Magnesium chloride hexahydrate (MgCl2) Merck
Magnesium sulfate heptahydrate (MgSO4) Merck
Mineral oil Sigma
N-2-Hydroxyethylpiperazine-N’-2-ethane sulfonic acid
(HEPES)
Biomol
Paraformaldehyde (PFA) Merck
Penicillin Gibco
Phosphocreatine disodium salt hydrate enzymatic (Na P-
creatine)
Sigma
Picrotoxin Sigma
Potassium chloride (KCl) Merck
Restriction enzymes Fermenatas
Potassium dihydrogen phosphate (KH2PO4) Merck
RiboRuler RNA ladder, High Range Ambion
Sodium chloride (NaCl) Merck
Sodium dihydrogen phosphate monohydrate (NaH2PO4) Merck
Sodium hydrogen carbonate (NaHCO3) Merck
Spermine Fluka Chemie
Streptomycin Gibco
Tetrodoxin citrate (TTX) BioTrend
Titriplex II (EDTA) Merck
Titriplex VI (EGTA) Merck
Trichlormethiazide (TCM) Sigma
Trypsin/EDTA Gibco
α-chymotrypsin Sigma
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4.1.2 Media and solutions
Name Recipe
BHK cells medium Glasgow MEM BHK-21 medium (Gibco), 10 %
Fetal bovine serum, 1 % Penicilin/Streptomycin
Slice-preparation medium MEM medium (Gibco), 1 % Peni-
cilin/Streptomycin, 1 % 1M Tris/HCl pH
7.2
Slice-culturing medium 50 % MEM medium (Gibco), 25 % HBSS
(Gibco), 25 % Horse serum, 0.5 % L-Glutamine
200 mM
PBS (10x) 100 mM Na2HPO4, 20 mM KH2PO4, 1.37 M
NaCl, 27 mM KCl
TAE (50x) in 1 l: 242 g Tris, 57.1 ml glacial acetic acid, 100
ml 0.5M EDTA (pH 8.0)
ORII in mM: 100 NaCl, 2 KCl, 1 MgCl2, 5 HEPES,
pH 7.5
Barth’s solution in mM: 88 NaCl, 1 KCl, 0.41 CaCl2, 0.82
MgSO4, 0.32 Ca (NO3)2, 10 HEPES, pH 7.6
ND96 in mM: 96 NaCl, 2 KCl, 1 MgCl2, 1.8 CaCl2, 5
HEPES, pH 7.4
Oocytes recording solution in mM: 90 NaCl, 1 KCl, 1.8 MgCl2, 10 HEPES,
pH 7.4
ACSF in mM: 119 NaCl, 2.5 KCl, 1.3 MgSO4, 1
NaH2PO4, 26.2 NaHCO3, 4 CaCl2, 4 MgCl2, 11
glucose
Internal recording solution in mM: 115 CsMeSO3, 20 CsCl, 10 HEPES. 2.5
MgCl2, 4 MgATP, 0.4 NaGTP, 10 Na P-creatine
0.6 EGTA, pH 7.2, 290 mOsm
4.2 Methods
4.2.1 General cloning methods
Digestion of DNA. 2-3 µg of DNA were digested with restriction enzymes to generate
DNA fragments with desired ”sticky” ends. DNA was cut with one or two enzymes. 1 µl of
enzyme (concentration 10U/µl) was used in a recommended buffer in total reaction volume
of 40-50 µl. The digestion time was at least 2h at recommended temperature. The efficiency
of digestion was tested on 1 % agarose gel desolved in TAE buffer. The fragment of interest
was cut from a gel and purified using the High Pure PCR Product Purification Kit (Roche).
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Ligation. DNA fragments were ligated using T4 DNA ligase (Invitrogen) in 5x buffer
provided by the manufacturer. The total ligation volume was 20 µl. Time of ligation was
either 2 hours at room temperature or over the night at 17◦C.
Electroporation of competent E. coli. 1-2 µl of ligation volume was mixed with 50µl
of E. coli competent cells, strain XL1 blue, in a 1 cm cuvette. The settings of Bio-Rad Gene
Pulser electroporator were: voltage 2.5 kV, resistance 400 ohms and capacitance 25 µFD.
1 ml of LB bacteria medium was added and cells were incubated at 37◦C for 1 hour with
constant agitation. The cells were collected by centrifugation (3 minutes at 800g) and plated
on agar plate supplemented with the appropriate antibiotic.
Plasmid isolation from E.coli. For ”mini-prep” of DNA one bacterial colony was
inoculated with 3 ml of LB/antibiotic media and incubated overnight at 37◦C. Cells were
transfered in 1.5 ml Eppendorf tubes and centrifuged at 17500g for 1 minute. Plasmids were
isolated using the QIAprep Spin Miniprep Kit (QIAGEN), based on the adsorption of DNA
from the bacterial lysate on the selective silica membrane in combination with high-salt
buffer.
Site-directed mutagenesis. Point-mutations were introduced in a DNA sequence using
PCR and Phusion High-Fidelity DNA polymerase (Finnzymes). This method employs two
pairs of primers. In the pair of mutagenic PCR primers one or more mutations were located
in the middle of the primer with 10-15 bases of the original template DNA sequence on
both sides. In two subsequent PCR reactions DNA fragment containing point mutations of
interest was amplified and subcloned into an appropriate vector.
4.2.2 In vitro transcription
GluR1, GluR2, GYKI- and CP-insensitive mutants, stargazin and Ex1 chimera were sub-
cloned into pTL vector (Lorenz et al., 1996) which contains SP6 RNA polymerase promoter
site. For RNA production, the constructs were linearized using MluI restriction enzyme.
GFP, PSD-95, PSD-93, both PSD-95/93 chimeras and Cdk5-phosphorylation mutants of
PSD-95 were cloned into pSFV vector for virus production, containing SP6 RNA polymerase
promoter site. For transcription plasmids were linearized with SpeI restriction enzyme.
100-200 ng of linearized DNA was used as a template for transcription using mMessage
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mMachine transcription kit (Ambion). The RNA was precipitated using LiCl precipitation
solution provided by the manufacturer and resuspended in nuclease-free water.
4.2.3 Xenopus oocytes preparation and injection
Xenopus laevis frogs were anesthetized with 1g of ethyl 3-aminobenzoate methanesulfonate
salt and 1g of NaHCO3 dissolved in 1l of water. Frogs were kept in anesthetizing solution
for 15-20 minutes. A 5-10 mm cut was made on one side of a frog abdomen and ovaries were
pulled out. Ovaries were cut into smaller lobes, 20-30 oocytes each and single oocytes were
isolated by collagenase treatment. 20 mg of collagenase type 3 (205 u/ml) was desolved in 20
ml of ORII solution. After 30 minutes of digestion with constant agitation, the collagenase
solution was changed with fresh solution and oocytes were digested for additional 30 minutes.
Oocytes were washed in Barth’s solution and remaining connective tissue and cells follicle
layers were removed manually with forceps. Stage V-VI oocytes were stored at 17◦C in ND96
solution supplemented with 50 µg/ml gentamycin.
Oocytes were injected with 50 nl cRNA. Injecting pipettes (World Precision Instruments,
Sarasota, FL) were filled with mineral oil and Nanoinjector II (Drummond Scientific Com-
pany) was used to inject the desired volume of RNA solution into oocytes. The amount
of injected RNA, relative amount of co-injected stargazin and time of expression varied
depending on the construct used (Fig. 5.9).
4.2.4 Two-electrode voltage clamp
After 1-2 days of expression glutamate-evoked currents were measured from oocytes using
two-electrode voltage clamp (TEVC). Schematic presentation of TEVC is shown in figure 4.1.
TEVC recordings were performed using a GeneClamp 500B amplifier connected to a Digidata
1322 controlled by pCLAMP 9.2 (Axon Instruments, Foster City, CA). Pipettes (World
Precision Instruments, Sarasota, FL) had a resistance of 0.5 - 1.5 MΩ and were filled with
3 M KCl. Glutamate evoked currents were recorded at -70 mV. Oocytes were continuously
perfused with the recording solution. Currents were evoked by 40 s applications of 200 µM
glutamate supplemented with 500 µM TCM to block AMPA receptor desensitization.
Dose-inhibition curves were constructed by applying 4-5 concentrations per oocyte of an-
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Figure 4.1: The principle of TEVC. The voltage electrode measures the resting potential of
an oocyte. The resting membrane potential is compared to a command potential and result-
ing current is injected through a current electrode to clamp the cell at the command voltage.
Glutamate and different antagonist were applied using the perfusion system.
tagonist mixed in agonist solution, and currents (I) were normalized to the current obtained
with agonist alone (I0). IC50 values were determined by sigmoidal fits following the equa-
tion: I/I0 = 1/
[
1 + 10(Log(IC50)−x)·HillSlope
]
. In the cases of imperfect fits we estimated
IC50 values from graphs. Data was analyzed with Prism 5.0 (GraphPad, San Diego, CA).
4.2.5 Surface labeling of oocytes
GluR1WT , GluR1GYKI and GluR1CP were tagged by inserting the HA epitope (YPYD-
VPDYA) three amino acids downstream from the signal peptide. Defolliculated oocytes
were injected with 5 ng HA-tagged GluR1 alone or with 5 ng of HA-tagged GluR1 and 1
ng stargazin cRNA. Uninjected oocytes were used as a negative control. Surface receptor
detection was performed two days after injection using chemiluminescence assay as described
(Zerangue et al., 1999). Oocytes were blocked in ND96-1% BSA solution for half an hour and
placed in a white flat-bottom 96-well plate, 5-7 oocytes per well. Oocytes were incubated for
1 h with 1 µg/ml rat anti HA antibody (3F10, Roche), followed by washing steps with ND96-
1% BSA, 3x10 minutes. Washing was performed in 6 cm dish. Oocytes were transfered to
96-well plate and incubated for 1 h with horseradish peroxidase-coupled secondary anti-rat
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IgG (Jackson Immuno Research), followed by 6x10 minutes washing steps. All washing and
incubation steps were performed at 4oC. Oocytes were placed into 96-well plates with 50
µl SuperSignal ELISA Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL) each.
Chemiluminescence was quantified using Mithras LB 940 luminometer (Berthold Technolo-
gies, Bad Wildbad, Germany) and 10-20 oocytes were averaged for each condition. The
signal of uninjected oocytes was substracted.
4.2.6 Organotypical hippocamapal slice preparation
Slices were prepared from 8 day old Wistar rats. Animals were decapitated and brains were
placed in the slice-preparation medium on ice for 1 minute. Hippocampi were isolated under
binocular and 400 µm thick slices were obtained using a McIlwain tissue culture chopper
(The Mickle Laboratory Engineering). Single slices were separated by gentle shaking in a
Falcon tube and undamaged slices were selected, transfered to fresh preparation medium
and incubated at 4◦C for 30 minutes to block the proteolytical processes in the slices.
Plate inserts were placed in 30 mm petri dishes with 1 ml of the slice-culturing medium.
Biopore 0.4 µm membrane (Millipore Corporation) was cut into small square pieces (”con-
fetti”) and 3-4 pieces were placed on a single insert. Slices were transfered onto the mem-
branes at the interface between air and culture medium and maintained at 35◦C, 5% CO2.
The culture medium was changed every second day.
4.2.7 Preparation of Semliki Forest virus
Semliki Forest virus (SFV) is a single-stranded RNA virus with an envelope structure. The
SFV genome is split into two vectors (Fig. 4.2). The expression vector contains the nonstruc-
tural genes (nsP1-4), subgenomic 26S promoter and multiple cloning site for introducing the
gene of interest. The structural proteins are provided from the helper vector containing the
capsid and envelope genes.
BHK cell preparation. To produce infectious virus particles, vector and helper RNA
obtained by in vitro transcription were mixed and co-transfected into BHK 21 (Hamster
Syrian Kidney) cells. BHK cells were transfered from a 90 % confluent 100 mm dish to a
150 mm dish in 1:10 dilution (2 ml of cell suspension in 18 ml BHK-medium). They were
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Figure 4.2: Maps of the pSFV and pSFV-helper plasmids used to generate recombinant SFV
particles. Regions encoding the non-structural proteins (nsP1-4), the structural proteins (c, E3,
E2, 6K and E1), the ampicillin resistance gene (Amp), SP6 promoter sites and multiple cloning
site (MCS) are indicated.
cultured until they reached 60 % confluency (approximately 2 days); confluence higher than
60 % makes cells resuspension more difficult and clumps are more easily formed. To collect
the cells for electroporation, 3 ml of trypsin/EDTA were added to a 150 mm dish and cells
were incubated for 3 minutes (longer incubation time may lead to cell death). To inactivate
trypsin, 17 ml of BHK-medium was added to the cells before the cells were transfered to a
50 ml Falcon tube and centrifuged for 3 minutes at 2500g. The supernatant was discarded
by aspiration and cells were washed with 20 ml of RNase-free 1xPBS and centrifuged again
for 3 minutes at 2500g. Supernatant was discarded and cell pellet was gently resuspended
in 0.5 ml RNase-free 1xPBS to obtain single cells.
BHK cell electroporation. 0.5 ml of cells suspension was transfered to sterile 0.2 cm
electroporation cuvette on ice. The RNA of pSFV containing gene of interest and pSFV-
hleper (≈20 µg each, i.e. total yield of both RNA reaction) were pre-mixed in the 1.5 ml
Eppendorf tube and added to BHK cells. Cells were electroporated using Bio-Rad electro-
porator. The settings were: voltage 1.5 kV, capacitance 25 µF, infinity resistance. Cells
were electroporated twice with an interval of 10-15 sec. Cells were mixed by finger flick-
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Figure 4.3: Schematic illustration of the production of replication-deficient SFV particles.
Both vectors are in vitro transcribed and co-transfected into BHK cells. Generated viral particles
are harvested and used to infect host cells. Adopted from (Lundstrom, 2003).
ing in between two electroporation. The time constant after each pulse was 0.7-0.8. After
electroporation, cells were left to recover for ≈10 minutes in cuvette at room temperature.
Electroporated BHK cells were added to 100 mm dish containing 9.5 ml BHK-medium, dish
was mixed and kept at 37◦C, 5% CO2.
Collection of viral particles. Transcription and translation of pSFV and helper vectors
via a BHK cell replication machinery results in formation of new infectious particles (Fig.
4.3). Since helper vector does not have packing signal, genes for structural proteins are not
included in formed viral particles. After one round of infection, new viral particles cannot
be formed, therefore the packed replicons are called ”suicide vectors”.
36 hours after electroporation the medium containing released viral particles was collected
33
4 Material and Methods
(10 ml) and centrifuged to spin down cell debris at 2500g for 10 minutes at 4◦C. Supernatant
was collected and kept at 4◦C. To concentrate viral particles, ultracentrifugation was per-
formed the same day. The supernatant was spun for 2h at 76800g and 4◦C using SW41 rotor.
The supernatant was aspirated leaving 200-300 µl in the tube. Viral pellet was resuspended
in this volume, split into 50 µl aliquots and stored at -80◦C.
Activation of the virus. pSFV-helper plasmid contains three point mutations in the
gene coding for structural protein that forms spikes necessary for the infection. Due to these
mutations the spike-forming protein is insensitive to endogenous proteases that results in
formation of nonfunctional spikes. Therefore the viral particles have to be activated, i.e.
treated with exogenous proteases.
50 µl of viral solution was digested for 45 minutes at room temperature with 1:20 volumes
of α-chymotripsin. α-chymotripsin was inactivated for 10 minutes at room temperature with
1:15 volumes aprotinin. Activated virus was aliquoted and stored at -80◦C.
4.2.8 Infection of hippocampal cultured slices
Hippocampal slices (6-10 DIV) were infected one day before recording. Injecting pipettes
(World Precision Instruments, Sarasota, FL) and Nanoinjector II (Drummond Scientific
Company) were used similarly as for oocytes injection (see section Xenopus oocytes
preparation and injection). 2-3 injections (23 nl each) of activated viral solution was
injected into CA2-CA1 area of hippocampus. Infected cells were visualized using GFP (Fig.
4.4).
4.2.9 Electrophysiology in slice culture
Pyramidal cells of the hippocampal slices were visualized using differential interference con-
trast camera on a fixed-stage upright microscope (Olympus, BX51WI). Recordings were
obtained from pairs of infected and uninfected cell simultaneously by stimulating Schaffer
collaterals using 2-3 MΩ glass electrodes (World Precision Instruments) filled with external
solution. Electrodes were pulled with P-97 micropipette puller (Sutter Instruments). Ex-
ternal solution was ACSF (artificial cerebro-spinal fluid) saturated with 95 % O2 and 5 %
CO2. To block inhibitory transmission 100 µM picrotoxin was added to external ACSF.
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Figure 4.4: GFP-positive cells from CA1 pyramidal cell layer one day after infection with SVF
vector expressing PSD-95:GFP.
Since spontaneous action potential firing in cultured hippocampal slices is very high, 20 µM
2-chloroadenosine was added to external solution to decrease presynaptic release probabil-
ity of neurons and suppress epileptic activity. Only MK-801 experiments were done in the
absence of 2-chloroadenosine. Isolated NMDA currents were measured in the presence of 10
µM NBQX and isolated AMPA currents in the presence of 100 µM APV in the external
solution. Cell recordings were made using 2-3 MΩ glass electrodes filled with the internal
solution. In the experiments where we measured rectification we included 0.1 mM sper-
mine in the internal solution. Data were collected using Axopatch 700B amplifier (Axon
Instruments) and digitized at 5 kHz with the Digidata 1322 controlled by pCLAMP 9.2.
Membrane and series resistance were monitored by applying -5 mV test pulse to cells after
obtainig the whole-cell configuration and only cells with input resistance lower than 20 MΩ
and membrane resistance higher than 100 MΩ were analyzed.
AMPA receptor-mediated EPSCs were evoked at -70 mV and EPSCs were recorded af-
ter adjusting stimulation strength so that AMPA currents in control cells were 50-100 pA.
The amplitude was determined by measuring the peak of response. After obtaining 20-30
sweeps, cells were depolarized to +40 mV, allowed to stabilize for 1 minute and another 40
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sweeps were measured. NMDA EPSC amplitude was determined by measuring the current
magnitude 70 ms after the stimulation artifact. Only sweeps 20-40 were taken for analysis.
In both cases, stimulation pulses were delivered at 0.2 Hz. Decay kinetic of isolated NMDA
currents was estimated as previously described (Cathala et al., 2005). Briefly, decay time
(τ) was calculated from the area under the current from peak to 1.3 s after the peak and
normalized to a peak amplitude.
4.2.10 Fixation and confocal microscopy
One day after infection slices were fixed with 4 % PFA in PBS for 20 minutes. Fixation was
proceeded by washing steps with PBS 3x10 minutes. After washing, slices were placed on
a microscope glass and maunted using maunting medium. Images were taken mainly the
day after the fixation using Leica DM IRE 2 (Leica Microsystems) microscope equiped with
63x oil emersion objective. Z-stacks of images were made with 0.1 µm thick sections and
maximal projections were obtained.
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5.1 Effect of stargazin on AMPA receptor antagonism
In neurons AMPA receptors are associated with their auxiliary subunits, TARPs. TARPs
regulate both the trafficking and biophysical properties of AMPA receptors. In our study we
focused on stargazin, the first TARP to be described as an auxiliary subunit of AMPA recep-
tors. It was previously shown that stargazin dramatically increased the surface expression
and glutamate evoked currents of AMPA receptors in Xenopus oocytes (Chen et al., 2003;
Tomita et al., 2004). Here, we used this system to investigate the effects of stargazin on the
antagonism of the competitive antagonist CNQX and the allosteric inhibitors GYKI-53655
and CP-465,022.
5.1.1 Effect of stargazin on GluR1 inhibition by CNQX, GYKI and CP
To study the inhibition of AMPA receptors, we injected the oocytes with GluR1 RNA alone
or together with stargazin RNA. As co-expression with stargazin increases the glutamate
evoked currents dramatically, we adjusted the amounts of injected RNA such that glutamate
evoked currents had similar amplitudes. Absolute current level evoked in oocytes injected
with 10 ng of GluR1 RNA alone was in the same order as when 0.1 ng of GluR1 RNA was
co-injected with 0.1 ng of stargazin RNA (Fig. 5.1A).
We tested whether stargazin influenced the efficacy of CNQX on GluR1 homomeric re-
ceptors. Interestingly, GluR1 was less inhibited by CNQX when co-expressed with stargazin
(Fig. 5.1A and B). Stargazin increased the IC50 for CNQX from 4.2 µM to 16.5 µM. What
could cause the shift in apparent CNQX sensitivity? At the same time with our finding,
it was shown that CNQX acts as a partial agonist at AMPA receptors co-expressed with
stargazin, but not at GluR1 alone (Menuz et al., 2007). Indeed, in our hands 100 µM of
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Figure 5.1: A, Representative traces of GluR1 glutamate-induced currents blocked by increas-
ing concentrations of CNQX with (left panel) or without stargazin (right panel), scale bars 1
µA, 50 s. B, Dose-response curves for GluR1 with and without stargazin in the presence of
CNQX and 200 µM glutamate. C, Dose-response curve for CNQX in the absence of glutamate,
showing that CNQX is a partial agonist. Each data point represents mean (±SEM) of 5-40
oocytes.
CNQX alone evoked currents from GluR1 co-expressed with stargazin; these currents reached
9 % ± 1 % of the currents evoked by the full agonist glutamate (200 µM) (Fig. 5.2). This
explains the shift of the IC50 towards higher concentrations of CNQX induced by stargazin.
To further characterize the partial agonistic effect of CNQX we measured the dose-response
curve of CNQX in the absence of glutamate. CNQX activated GluR1 receptors with an
EC50 of 0.5 µM (Fig. 5.1C).
Next we asked the question which part of stargazin is responsible for the change in CNQX
affinity. Tomita and co-workers showed that the first extracellular loop of stargazin controls
gating, whereas the C-terminus is important for trafficking AMPA receptors to the surface
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Figure 5.2: Dose-response curves of CNQX for GluR1 alone and upon co-expression with
stargazin and Ex1. Bar graph shows that 100 µM CNQX alone evokes currents from GluR1
co-expressed with stargazin, but does not activate GluR1 co-expressed with Ex1. GYKI and CP
alone did not evoke any currents. Each data point represents mean (±SEM) of 9-16 oocytes.
(Tomita et al., 2005). We took advantage of a construct where the ectodomain of stargazin
is replaced by that of γ-5, the protein most similar in sequence to TARPs that does not
regulate AMPA receptors. This γ-5-stargazin chimera (Ex1) mediates receptor trafficking
but does not slow receptor desensitization and deactivation (Tomita et al., 2005).
The inhibiting effect of CNQX on GluR1 co-expressed with Ex1 was not different from
GluR1 alone (Fig. 5.2). CNQX did not evoke detectable currents from GluR1 co-expressed
with Ex1 (Fig. 5.2). This suggests that the ectodomain of stargazin is essential for the
partial agonistic effect of CNQX.
We next focused on allosteric inhibitors, and compared their antagonism in the absence
and presence of stargazin. We tested GYKI-53655 (in further text GYKI), a non-competitive
inhibitor of 2,3-benzodiazepines family, and CP-465,022 (in further text CP), a quinazilonone
derivative. Stargazin greatly increased the affinity of GluR1 for GYKI (IC50: -Stg ≈100 µM;
+Stg 38.5 µM) (Fig. 5.3A). In contrast the affinity for CP was only modestly affected by the
presence of stargazin (IC50 -Stg 1.1 µM; +Stg 0.6 µM) (Fig. 5.3B). To test whether GYKI
and CP also have partial agonistic effect on GluR1 homomers associated with stargazin, we
applied 300 µM GYKI or 30 µM CP in the absence of glutamate on GluR1 co-expressed
with stargazin. No currents could be evoked by either GYKI or CP alone (Fig. 5.2).
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Figure 5.3: Dose-response curves of GYKI (A) and CP (B) for GluR1 and GluR1 + stargazin.
Each data point represents mean (±SEM) of 5-40 oocytes.
5.1.2 Dependence of increased GluR1 sensitivity on the desensitization
It was debated in earlier studies that GYKI and the allosteric modulator cyclothiazide (CTZ)
bind to the same domain of AMPA receptors (Donevan and Rogawski, 1993; Zorumski et al.,
1993). Balannik and colleagues suggested that manipulations, which reduce AMPA receptor
desensitization, decrease the inhibitory effect of GYKI and CP (Balannik et al., 2005). The
increased affinity for GYKI in the presence of stargazin (Fig. 5.3A) could be an effect of
blocked desensitization caused by TCM, a positive modulator structurally similar to CTZ
(Mitchell and Fleck, 2007; Yamada and Tang, 1993). Therefore, we recorded glutamate
evoked currents from GluR1WT in the absence of TCM (fully desensitizing receptor) and
from the non-desensitizing GluR1 mutant L497Y (GluR1LY ) (Stern-Bach et al., 1998) in the
absence and presence of stargazin (Fig. 5.4A and B). Similarly as in the presence of TCM
stargazin shifted the sensitivity of GluR1WT to lower concentrations (IC50: -Stg ≈ 200 µM;
+Stg 28 µM), (Fig. 5.4A). This indicates that the change by stargazin is not an effect of
altered desensitization.
In agreement with published data, GluR1LY was less blocked by GYKI than GluR1WT
(Fig. 5.4B) (Balannik et al., 2005). However, there was no difference in the antagonism
of GYKI on GluR1LY when co-expressed with stargazin (IC50: -Stg 300 µM; +Stg 300
µM). While stargazin enhanced the surface trafficking of GluR1LY , it did not increase the
glutamate evoked currents of GluR1LY (Tomita et al., 2007). Together with our finding
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Figure 5.4: A, Dose-response curve of GluR1WT for GYKI in the absence of TCM. B, Dose-
response curves of GYKI for GluR1LY in the presence and absence of stargazin. Each data
point represents the mean (±SEM) of 14 oocytes.
this might suggest that LY mutation either alters the confirmation of the linker domains or
changes the agonist efficacy occluding the effect of enhanced GYKI affinity in the presence
of stargazin.
5.1.3 Effect of stargazin on GYKI- and CP-insensitive GluR1 mutants
Recently the binding sites for GYKI and CP were identified at the interface of the extra-
cellular agonist-binding core and the transmembrane domains. The binding domains are
located at the S1-M1 and S2-M4 linkers and comprise in total five changed residues (see
Methods) (Balannik et al., 2005). The authors suggested that GYKI and CP interact with
the S1-M1 and S2-M4 linkers, thereby disrupting the transduction of agonist binding into
channel opening.
We used GYKI- and CP-insensitive variants of GluR1 (GluR1GYKI and GluR1CP ) to
further investigate the effects of stargazin on the antagonism of the allosteric inhibitors. In
agreement with published results GluR1GYKI and GluR1CP were not blocked by GYKI or
CP (Fig. 5.5A and B). Surprisingly, the GYKI-insensitive mutant GluR1GYKI regained its
sensitivity to GYKI in the presence of stargazin (IC50: -Stg not determined; +Stg 100
µM, Fig. 5.5A). In contrast, the CP-insensitive mutant GluR1CP when co-expressed with
stargazin was only modestly inhibited by higher concentrations of CP (Fig. 5.5B). Together
with the finding that stargazin has only small effects on CP affinity (Fig. 5.3B), this suggests
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Figure 5.5: Dose-response curves of GYKI on GluR1GYKI (A), and CP on GluR1CP (B) in
the presence and absence of stargazin.
that the binding sites for GYKI and CP might be distinct in GluR1 co-expressed with
stargazin, and that stargazin only affects the GYKI site strongly.
We showed that CNQX partial agonistic effect, as well as the effect of stargazin on CNQX
inhibition dose-response curve were fully abolished when GluR1 was co-expressed with Ex1
(Fig. 5.2). Does the same domain of stargazin control the effect on allosteric inhibitors?
When co-expressed with Ex1, the dose response curve of GluR1WT for GYKI was shifted
toward higher concentrations compared to GluR1WT alone (Fig. 5.6A). This suggests that
mutated stargazin influences the efficacy of GYKI; however, Ex1 could have additional ef-
fects causing this shift. To further confirm that the ectodomain of stargazin modulates the
antagonism of AMPA receptors, we co-expressed Ex1 with GluR1GYKI . Here, the enhancing
effect of stargazin was completely abolished with Ex1 (Fig. 5.6B).
5.1.4 Inhibition of GluR2WT and GluR2 GYKI- and CP-insensitive mutants
To test the generality of the stargazin modulation of allosteric antagonism, we looked at
the antagonism of GYKI and CP on GluR2 homomeric receptors. As the expression levels
of GluR2 are extremely low without stargazin in heterologous expression systems, we only
compared GluR2 to the insensitive mutants GluR2GYKI and GluR2CP when co-expressed
with stargazin. First, we noticed that GluR2WT has a lower affinity for GYKI compared
to GluR1WT (GluR1WT + Stg: IC50 = 38.5 µM; GluR2WT + Stg: IC50 = 100 µM) (Fig.
5.7). Similar to GluR1GYKI , in the presence of stargazin GluR2GYKI was sensitive to GYKI
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Figure 5.6: Dose-response curves of GYKI for GluR1WT (A) and GluR1GYKI (B) in the
presence of stargazin and Ex1 chimera.
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Figure 5.7: Dose-response curve of GYKI on GluR2GYKI (A) and CP on GluR2CP (B)
compared to GluR2WT response in the presence of stargazin. Each data point represents mean
(±SEM) of 9-42 oocytes.
(Fig. 5.7A). In contrast, CP potently inhibited GluR2 co-expressed with stargazin, while
the insensitive mutant GluR2CP was not blocked by this drug (Fig. 5.7B). As the observed
effects of the antagonists are qualitatively similar for GluR1 and GluR2, it seems that the
mechanism of inhibition does not strongly depend on the subunit of AMPA receptors.
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5.1.5 Glutamate-dose response of GluR1WT and GluR1 insensitive mutants
During the course of our experiments we noticed significantly smaller glutamate evoked
currents mediated by GluR1GYKI , but similar current levels for GluR1CP compared to
GluR1WT . What reduces the current of GluR1GYKI? Either the efficacy of glutamate
to activate the receptor is impaired such that the receptors are not fully activated by the
glutamate concentration used, or the number of receptors at the surface is reduced.
First, we tested the glutamate affinity of the mutated receptors. As reported previously,
stargazin increased the affinity for glutamate of GluR1WT (Fig. 5.8) (Tomita et al., 2005).
Interestingly, the EC50 of GluR1GYKI and GluR1CP in the absence of stargazin was strongly
increased to the level of GluR1WT co-expressed with stargazin. Stargazin increased the gluta-
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Figure 5.8: Glutamate-dose response curves for GluR1WT (A), GluR1GYKI (B) and GluR1CP
(C) in the presence and absence of stargazin. Each data point represents mean (±SEM) of 8-10
oocytes. D, EC50 values obtained from the curves in A, B and C.
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Figure 5.9: A, Surface expression of HA-tagged GluR1 receptors in the presence and absence of
stargazin. Bars represent averages of 10-20 oocytes (±SEM).B, Oocytes expressing GluR1GYKI
show similar glutamate evoked currents as GluR1WT and GluR1CP when injected with the
higher amounts of RNA and after longer expression time.
mate affinity of GluR1GYKI only modestly and had no effect on GluR1CP (EC50: GluR1WT
- Stg = 10.94 µM, + Stg 4 µM; GluR1GYKI - Stg = 6.2 µM, + Stg = 4.6 µM; GluR1CP -
Stg = 3.4 µM, + Stg = 3.4 µM). This shows that we fully activated all expressed receptors
with the glutamate concentration used (200 µM).
5.1.6 Surface expression of GluR1 insensitive mutants
As an incomplete activation of the mutated receptors could not account for the current
reduction we compared the surface expression of GluR1WT to GluR1GYKI and GluR1CP
expressed with and without stargazin. We used hemagglutinin (HA) tagged receptors to
monitor the surface expression by chemiluminescence (Tomita et al., 2005; Zerangue et al.,
1999). The tagging of GluR1WT did not affect the current size compared to untagged
receptors (data not shown). To compare surface expression we injected identical amounts of
RNA. GluR1WT homomeric receptors reached the surface, and coexpression with stargazin
significantly increased the surface expression (GluR1 + Stg: 16.9 ± 1.2 a.u., n = 20; GluR1:
4.0 ± 0.6 a.u., n=19) (Fig. 5.9A). In contrast, GluR1GYKI was found only in limited amounts
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at the surface (GluR1GYKI + Stg: 1.7 ± 0.7 a.u., n=10; GluR1GYKI 0.2 ± 0.1 a.u., n=19).
Surprisingly, trafficking of GluR1CP to the surface was also impaired (GluR1CP + Stg: 3.8
± 0.7 a.u., n=19; GluR1CP 0.4 ± 0.1 a.u., n=17). This indicates that the trafficking of the
mutated receptors to the cell surface is impaired. We compensated for the lower expression
levels of GluR1GYKI by injecting higher amounts of RNA and longer expression times to
obtain similar magnitudes of glutamate-evoked currents (Fig. 5.9B).
Together, these data indicate that the GYKI and CP mutations not only affect antagonist
binding, but also change receptor trafficking and possibly also channel gating.
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5.2 Regulation of synaptic function by PSD-95
Trafficking of AMPA and NMDA receptors controls the excitatory synaptic transmission.
The synapses in the brain are highly plastic implying that synaptic receptors are dynamic
and their trafficking, insertion, and internalization is tightly regulated. Insertion and removal
of AMPA receptors are mechanisms underling synaptic plasticity. NMDA receptors are often
regarded as a relatively stable complex in the postsynaptic membrane. However, recent
studies suggest that they also move in the membrane via lateral diffusion (Zhao et al., 2008)
and that subunit-composition switch of synaptic NMDA receptors is rapid in the neonatal
synapses (Bellone and Nicoll, 2007). AMPA receptors are localized to synapses through
binding of stargazin to PSD-95 (Schnell et al., 2002), whereas PSD-95 binds directly to the
NR2 subunit of NMDA receptors. However the majority of the present data suggest that
PSD-95 affects selectively AMPA currents with no effect on NMDA currents (Schnell et al.,
2002; Stein et al., 2003; Beique and Andrade, 2003). Acute knockdown of PSD-95 in cultured
brain slices decreases selectively AMPA currents (Elias et al., 2006), while in another study
a smaller decrease in NMDA currents accompanied the AMPA currents decrease (Ehrlich
et al., 2007).
Some studies reported that PSD-95 affected the presynaptic properties of a synapse. When
overexpressed in dissociated hippocampal neurons, PSD-95 led to the presynaptic develop-
ment since FM4-64 labeling was enhanced in presynaptic boutons opposing the PSD-95
overexpressing spines (El-Husseini et al., 2000). Futai and collegues reported that PSD-95
modulates the presynaptic release through retrograde signaling mediated by an interaction
with neuroligin (Futai et al., 2007). However, PSD-95 has not been found to alter presynaptic
release probability in cortical pyramidal neurons (Beique and Andrade, 2003).
Given this discrepancy in the published data about the effect of PSD-95 overexpression on
synapse function, we infected CA1 hippocampal neurons with PSD-95:GFP fusion protein
and investigated both presynaptic and postsynaptic changes in infected cells. In addition,
we performed some experiments under different experimental conditions and addressed the
question what could be the reason for different data obtained in different labs.
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Figure 5.10: A, Illustration of the experimental approach used for the simultaneous recording
from two cells in a slice. B, Example traces of non-infected (black) and infected cells (green)
at -70 mV and +40 mV. AMPA currents are measured as peak currents at -70 mV and NMDA
currents are measured at +40 mV, 70 ms after the stimulus (indicated by arrows). Membrane
and series resistance were monitored by applying -5 mV test pulse before the stimulus.
5.2.1 Simultaneous recordings from two cells in slice
To assess the changes in synaptic function, we measured evoked AMPA and NMDA currents
in infected cell and compared the amplitudes to a neighboring control, non-infected cell (Fig.
5.10A). AMPA currents were evoked by stimulating Schaffer collaterals at -70 mV. NMDA
currents were measured at +40 mV, 70 ms after the stimulus artifact when AMPA currents
have completely decayed. Figure 5.10B shows example current traces at -70 mV and +40
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mV of a control and a PSD-95-overexpressing cell recorded simultaneously.
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Figure 5.11: A, EPSC amplitudes distribution of two neighboring control cells. B, EPSC
amplitudes distribution of GPF-infected and control cell. Each black dot on the scatter plots
represents amplitudes for single pairs and red dot represents the mean.
First, we tested whether two neighboring control cells in a slice had same amplitudes given
that they received same stimulus intensity. Two cells were recorded simultaneously in two
different channels, 1 and 2. Measured currents were analyzed and presented in two different
ways. In figure 5.11, scatter plots present the current amplitudes of cells in each pair (black
dots). Cells recorded in channel 1 are plotted on X-axis and those recorded in channel 2 on
Y-axis. The red dot represents the average amplitudes of each of the groups plotted as one
pair. The dashed line in the scatter plots is included for the easiness of interpreting data in
the graphs. When two cells of a pair have the same amplitude, the dot lays on the dashed
line. The dots are shifted towards one of the axises when one group of the cells have larger
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amplitudes.
Another way to present the data from paired recordings is to calculate the ratio between
two cells (i.e. ratio = amplitude1 / amplitude2) and calculate the average ratio ± SEM.
This is presented in the bar graphs in figure 5.11.
For both AMPA and NMDA currents of control cell pairs, the red dot was located close
to the line, indicating that average amplitudes of the two cell groups were the same (Fig.
5.11A, scatter plots). However, the average ratio for AMPA currents was 0.9 ± 0.1 and
for NMDA currents 1.3 ± 0.1 (Fig. 5.11A, bar graph). Given the distribution of NMDA
amplitudes in the scatter plot, an average ratio of amplitudes of 1.3 ± 0.1 seems unexpected.
This suggested that different ways of analyzing data, i.e. average ratio of amplitudes vs.
ratio of average amplitudes could give different outcome.
The question remains whether 1.3-fold larger amplitudes in one cells group is significantly
different from amplitudes in the second group. What would be the appropriate statistical
test for this? The fact that current amplitudes vary significantly within the same cell from
one sweep to another (which we did not take in consideration in our analysis) additionally
complicates the interpretation of the data. Additional analysis, which are not in the scope
of this study, will be necessary to address this problem. Throughout this study we presented
both scatter plots and bar graphs.
PSD-95 used in this study was fused to GFP. To test whether GFP expression alone had
some effect on the synaptic currents, we overexpressed GFP using the Semliki Forest virus
system and recorded from infected and neighboring control cell (Fig. 5.11B). The average
ratio between GFP overexpressing cell and control cell was 0.9 ± 0.1 for AMPA current and
1.1 ± 0.2 for NMDA current.
From these two control experiments we concluded that simultaneous recording from two
neighboring cells in the slice was reliable approach to directly compare current size of the
two cells.
5.2.2 Effect of PSD-95 overexpression on synaptic AMPA and NMDA currents
PSD-95 is a scaffolding protein located in the spines of glutamergic synapses (Cho et al.,
1992). We tested whether the PSD-95:GFP fusion protein used in our study had normal spine
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GFP PSD-95:GFPA B
Figure 5.12: A, Confocal image of GFP infected CA1 cell in organotypical hippocampal slice.
Scale bars: left panel 20.2 µm, right panel 6.4 µm. B, PSD-95 overexpressing cell showing
PSD-95 localization to synaptic spines. Scale bars: left panel 27.7 µm, right panel 6.0 µm.
localization. Unlike GFP, which showed homogeneous distribution in both dendritic shafts
and spines, CA1 hippocampal neurons overexpressing PSD-95:GFP showed a punctated GFP
signal pattern, indicating that PSD:GFP was localized to spines (Fig. 5.12A and B).
As reported in previous studies (Schnell et al., 2002; Stein et al., 2003; Ehrlich et al., 2007;
Beique and Andrade, 2003), we observed that the AMPA receptor component of excitatory
currents was dramatically increased in the cells overexpressing PSD-95 (Fig. 5.13A and B).
On average, the infected cell had 4.5 ± 0.4-fold larger AMPA current than the neighboring
control cell. Interestingly, the NMDA receptor component was also increased. The infected
cells showed on average 1.8 ± 0.1-fold increase (Fig. 5.13A and B). We correlated the AMPA
and NMDA EPSCs increase for each pair and for the most of the cells there was a correlation
between AMPA and NMDA current increase (Fig. 5.13C). That led us to a hypothesis that
a synapse with higher AMPA receptor component would most likely have higher NMDA
receptor component. We discussed that further in the section 5.2.4.2.
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Figure 5.13: A, Distributions of EPSC amplitudes show an increase in AMPA and NMDA
currents for PSD-95-infected cell. B, Average increase for AMPA and NMDA currents. C,
Plotted AMPA and NMDA EPSC ratios of each cell pair. AMPA and NMDA ratios of the same
pair are connected with a line.
5.2.2.1 Impact of different experimental conditions on the PSD-95 effect
Given that NMDA receptors interact directly with PSD-95, one would expect an increase
in NMDA currents upon overexpression of PSD-95. However, most of the previous studies
published did not observe such an effect. In order to address the question what could be the
possible reason for this difference, we measured AMPA and NMDA currents from PSD-95-
overexpressing and control cells under experimental conditions used in the other studies.
First we changed the rat strain we used for obtaining hippocampal slices. Initially, we
used Wistar rats whereas all of the previous studies used slices from Sprague Dawley rats.
We hypothesized that two strains may differ in the protein expression profiles of either
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Figure 5.14: Distributions of EPSC amplitudes show an increase in both AMPA and NMDA
currents in PSD-95-infected cell in the Sprague Dawley slices.
members of MAGUK family or NMDA receptors subunits or other proteins involved in
NMDA receptors trafficking and function. Therefore we overexpressed PSD-95 in Sprague
Dawley slices and tested the effect of PSD-95 on AMPA and NMDA currents. We could
still observe an effect on both AMPA and NMDA currents (Fig. 5.14). The ratio between
infected and control cell was 5.2 ± 1.1 for AMPA receptor component and 2.3 ± 0.3 for
NMDA receptor component. The increase in EPSCs was even slightly larger in Sprague
Dawley slices. All the following experiments we performed using slices from the Wistar rats.
Another possible reason for the difference in the PSD-95 effects observed in different labs
could be different culturing conditions of slices. Namely, antibiotics like penicillin and strep-
tomycin, are often included in slice media to prevent the slice contamination. Interestingly,
effects of these antibiotics on synaptic transmission have been reported. For example, peni-
cillin is GABA-A receptors antagonist that can lead to epileptiform bursting when applied
to slice cultures (Schneiderman et al., 1994). This bursting in turn causes NMDA-dependent
plastic changes which produce long-lasting network oscillations in vitro. On the other hand,
aminoglycosides like streptomycin, kanamycin and neomycin, are shown to modulate the
agonist response of NMDA receptors in a similar manner that extracellular polyamines do
(Harvey and Skolnick, 1999). In particular, they potentiate the agonist responses in a glycin-
dependent and voltage-independent manner. Taking these data in consideration, it could be
possible that the PSD-95 effect on NMDA receptor component was masked in the previous
studies due to the action of penicillin and/or streptomycin.
When we cultured the slices from the Wistar rats in the presence of penicillin and strepto-
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Figure 5.15: Distributions of EPSC amplitudes show an increase in both AMPA and NMDA
currents in PSD-95-infected cell in Wistar slices cultured in the presence of penicillin and strep-
tomycin.
mycin we could still observe PSD-95-mediated potentiation in both AMPA (5.8 ± 0.5-fold)
and NMDA (3.2 ± 0.4-fold) currents (Fig. 5.15). Both AMPA and NMDA receptor com-
ponent were enhanced more strongly in the presence of antibiotics than in the absence of
antibiotics. For the rest of the study we omitted antibiotics in our culturing medium.
Beside the culturing conditions, we also varied some recording conditions. In particular,
when rectification of AMPA receptors is measured, the polyamine spermine is included in the
patch pippete. Spermine blocks Ca2+-permeable AMPA receptors at positive potentials and
makes rectification more pronounced and easier to measure. Interestingly, spermine exhibits
an effect also on NMDA receptors. It has been reported that intracellular spermine has a
direct inhibitory effect on NMDA receptors by decreasing the open probability of NMDA
receptor channels in a dose-dependent manner (Turecek et al., 2004).
When we included 0.1 mM spermine in the intracellular solution the AMPA receptor
component was still increased in PSD-95-overexpressing cells (Fig. 5.16), though to lower
extent compared to the other conditions (3.3 ± 0.8-fold), whereas the NMDA currents were
enhanced in the similar manner (2.3 ± 0.4-fold).
The PSD-95 effect on both AMPA and NMDA currents was therefore consistent in all
experimental conditions we used. The summary of the results is shown in figure 5.17. There
may be some other causes for the observed differences between us and other labs. For exam-
ple, the expression level of PSD-95 in the infected cells may be higher under our conditions,
therefore leading to more robust effect on AMPA currents, but also enabling the effect on
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Figure 5.16: Distributions of EPSC amplitudes show an increase in both AMPA and NMDA
currents for PSD-95-infected cell recorded in the presence of 0.1 mM spermine in the intracellular
solution.
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Figure 5.17: Summary of all conditions used and the corresponding AMPA and NMDA ratios
between infected and control cells. ”Regular” refers to the culturing in the absence of antibiotics
and recording with the intracellular solution without spermine.
NMDA currents to be measured. The other factors, such as onset and length of PSD-95
expression, may be important. Alternatively, the number of manipulated neurons in the
network may affect the outcome.
5.2.2.2 Measurements of isolated NMDA currents
We measured NMDA current as a late component (70 ms after the stimulus) of the com-
pound current at + 40 mV. To exclude a possibility that our measured NMDA current was
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Figure 5.18: NMDA EPSCs distribution measured at +40 mV in the presence of NBQX and
at -70 mV in the presence of NBQX and low magnesium concentration.
contaminated by AMPA component that had not fully decayed at 70 ms, we isolated NMDA
currents by blocking AMPA currents with 10 µM NBQX included in the recording solution.
NMDA EPSC amplitude was measured as a peak current at +40 mV. NMDA currents mea-
sured from cells overexpressing PSD-95 showed 1.8 ± 0.1-fold potentiation compared to the
control cells, same potentiation we observed when NMDA currents were measured as a late
component of compound current without NBQX in the bath (Fig. 5.18).
Another way to measure NMDA currents is to record a cell at -70 mV in a low magnesium
concentration (0.1 mM). Under these conditions NMDA receptors are not blocked by Mg2+,
so no depolarization is necessary to release the block. Measuring at negative potentials, i.e.
being closer to the cell resting potential, leads to the smaller ”voltage escape” (Williams and
Mitchell, 2008). Namely, the synaptic potentials are progressively attenuated as they spread
from the site of origin (dendritic tree) to the soma where they are measured. Therefore, in
order to measure the NMDA currents more accurately, we clamped the cell at -70 mV in the
presence of low Mg2+ and NBQX and compared the amplitudes of PSD-95 overexpressing cell
and control cell. Again the PSD-95 cells showed 1.8 ± 0.2-fold increase in NMDA currents,
similar to the other measurements (Fig. 5.18).
From these data we concluded that increased NMDA currents we observed were not a
measurement artifact.
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5.2.3 Presynaptic effects of PSD-95 overexpression
From the data shown above we concluded that overexpression of PSD-95 leads to the robust
increase in AMPA receptor component, as reported by others, and milder, but significant
increase in NMDA receptor component. The next step was to investigate what underlies
this enhancement of synaptic strength in PSD-95-overexpressing cells.
Some studies suggested that PSD-95 might affect the presynapse by a retrograde mecha-
nism and change the release probability of neurons (Migaud et al., 1998; El-Husseini et al.,
2000; Futai et al., 2007). To test if PSD-95-infected cells in cultured hippocampal slices have
altered release probability, we used several experimental paradigms to monitor for presynap-
tic changes.
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Figure 5.19: A, Example current traces of control and PSD-95-infected neuron as response to
successive stimuli (40 ms interval). B, Bar graphs representing the average paired-pulse ratio
obtained from 19 cells for each condition.
5.2.3.1 Paired-pulse ratio in PSD-95-infected cells
Paired-pulse ratio (PPR) is a measurement of the presynaptic release probability. In this
paradigm we delivered two stimuli to a cell in a 40 ms interval and calculated the ratio
between the second and the first synaptic response (Fig. 5.19A). At 40 ms inter-stimulus
interval the ratio between the second and the first amplitude was larger than 1. This facili-
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tation of the second synaptic response can be explained by residual Ca2+ in the presynapse
after the first stimulus.
As shown in figure 5.19B, the PPR values of control and PSD-95-infected cells were not
significantly different (1.8 ± 0.1 and 1.7 ± 0.1, respectively), indicating that PSD-95 does
not alter presynaptic release probability.
5.2.3.2 NMDA receptor block by MK-801
To further test for the modulation of presynaptic release by PSD-95, we used MK-801,
an open-channel blocker of NMDA receptors. In the presence of MK-801, isolated NMDA
currents are blocked in a stimulus-dependent way; this block occurs at a faster rate at
synapses with higher release probability and a slower rate at synapses with lower release
probability. Decay curves were fit with single exponential function and decay constants were
given in the stimulus number. We compared block of control and PSD-95-overexpressing
cell in the presence of 40 µM MK-801. The rate of block of NMDA receptors in cells
overexpressing PSD-95 was not significantly different from control cells: control: τ= 25
stimuli, PSD-95: τ=23 stimuli (Fig. 5.20A), indicating that there was no difference in the
release probability between the two groups.
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Figure 5.20: A, Averaged normalized NMDA receptor EPSCs during the perfusion with MK-
801 for control and PSD-95 overexpressing cell (n=18 pairs). B, Control cells from the experi-
ment in (A) were compared to 11 control cells measured in the absence of 2-ClAd. Amplitudes
are the average of each five consecutive EPSCs normalized to that of the first five averaged
EPSC in the presence of MK-801.
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In order to test that we could measure the differences in release probability using this
method, we compared the decay kinetics of control cell in the absence and in the presence of 2-
chloroadenosine (2-ClAd). 2-ClAd decreases release probability by acting on the presynaptic
adenosine receptors. As expected, the block of cells by MK-801 was faster in the absence
of 2-ClAd than in the presence (Fig. 5.20B). Decay constants for the control cells in the
presence of 2-ClAd was τ= 47 stimuli.
5.2.3.3 Sensitivity of release probability to extracellular Ca2+
Futai and co-workers found that overexpression of PSD-95 increases the sensitivity of presy-
naptic release machinery to extracellular Ca2+, which leads to higher AMPA and NMDA
currents in PSD-95-overexpressing cells (Futai et al., 2007). When extracellular concentra-
tion of Ca2+ was increased to saturating concentration (10 mM, release probability maximal),
difference between control and PSD-95 cell was occluded. As another test for presynaptic
effects of PSD-95, we compared the NMDA current-ratio between infected and control cell
in the presence of 2 mM and 10 mM Ca2+ concentrations to the one we already measured
in 4 mM Ca2+.
1 10
0
1
2
3
[Ca2+]out (mM)
EP
SC
in
f /
 E
PS
C
co
nt
ro
l
Figure 5.21: NMDA EPSCs ratios of PSD-95-infected to control cells in different extracellular
Ca2+ concentration. Number of cell pairs: 2 mM, 10; 4 mM, 18; 10 mM, 8; 4 mM w/o 2-ClAd
(gray), 7.
If enhancing effect of PSD-95 on NMDA currents resulted from higher release probability
in infected cells, the NMDA ratio should be lower at higher Ca2+ concentrations. We could
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not observe any significant differences (one way ANOVA test) in NMDA EPSCs enhancement
in all concentrations tested: 2 mM: 1.5 ± 0.4; 4 mM: 1.8 ± 0.1; 10 mM: 2.2 ± 0.3 (Fig.
5.21). In addition, we measured the infected to control cell NMDA EPSC ratio in 4 mM
Ca2+ in the absence of 2-ClAd. Under this condition the release probability was higher than
in the presence of 2-ClAd, but the ratio we measured was not different from the one in the
presence of 2-ClAd (1.7 ± 0.7, Fig. 5.21).
From these data we concluded that overexpression of PSD-95 in the postsynaptic cell did
not lead to functional changes in opposing presynaptic boutons.
5.2.4 Postsynaptic effects of PSD-95 overexpression
Overexpression of PSD-95 led to enhanced AMPA and NMDA currents. We concluded
that this enhancement was not mediated by the presynaptic changes. What could be the
postsynaptic mechanisms that mediated this enhancement? Expression of PSD-95 increases
the number of synaptic AMPA receptors by mechanism that requires the interaction of
PSD-95 with stargazin (Schnell et al., 2002; Ehrlich et al., 2007). PSD-95, similarly to
LTP, increases the amplitude and frequency of mEPSCs and converts silent synapses to
functional synapses (Stein et al., 2003). How are the NMDA receptors currents increased
upon overexpression of PSD-95? One possibility is that the composition of synaptic NMDA
receptors is changed leading to the higher amplitudes or that PSD-95 changes functional
properties of existing NMDA receptors. Another possibility is that, similarly to AMPA
receptors, the number of synaptic NMDA receptors is increased.
5.2.4.1 PSD-95 overexpression and NMDA receptors subunit composition
NR2B-containing NMDA receptors have a slower decay kinetic compared to NR2A-contain-
ing receptors and are selectively blocked by the antagonist ifenprodil (Cull-Candy and
Leszkiewicz, 2004). Overexpression of PSD-95 could recruit more NR2B-containing NMDA
receptors to synapses. That would result in both slower decay of the currents and higher
EPSC amplitudes. We calculated the decay time as previously described (Cathala et al.,
2005) (see also Methods) from the traces of isolated NMDA currents measured at +40 mV
in the presence of NBQX (Fig. 5.18). The decay constant was not significantly different be-
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Figure 5.22: Bar graphs of NMDA EPSC decay time constants obtained from 19 cell pairs.
tween PSD-95 overexpressing and control cell: 0.14 ± 0.01 s and 0.13 ± 0.01 s, respectively.
This result indicates that overexpression of PSD-95 did not lead to a change in the NMDA
receptors subunit composition.
There is evidence that PSD-95 changes some of the channel properties of NMDA recep-
tors. Li and colleagues reported that during development NMDA receptor desensitization is
decreased and this was not dependent on the subunit switch but was correlated with synap-
tic localization of the receptors (Li et al., 2003). The authors showed that overexpession
of PSD-95 reduced the NMDA receptor desensitization in immature neurons, whereas un-
coupling of the receptors from PSD-95 in mature neurons increased receptors desensitization.
In a more recent study Sornarajah and colleagues found that NMDA receptor desensitization
is regulated by direct binding of PSD-95 (Sornarajah et al., 2008). We did not follow up this
hypothesis, but we could not exclude the possibility that PSD-95 exhibited some effects on
NMDA receptor biophysical properties.
5.2.4.2 Coordinated trafficking of AMPA and NMDA receptors
After excluding the presynaptic effect of PSD-95 expression and a change in a subunit-
composition of NMDA receptors, we concluded that PSD-95 increases the number of NMDA
receptors. This increase was not as robust as increase in AMPA receptors number, even
though PSD-95 interacts directly with NMDA receptors and only indirectly with AMPA
receptors.
61
5 Results
We asked the question whether increased NMDA currents were a direct effect of PSD-
95 or an indirect effect, i.e. a consequence of the increased number of AMPA receptors.
Trafficking of AMPA receptors and NMDA receptors is mostly considered to be independent,
as for example in LTP where AMPA receptors are rapidly and selectively inserted into the
synapse. But this raises the question of how a constant AMPA/NMDA ratio is preserved
in the synapses with ongoing plasticity. Turrigiano and colleagues reported that upon LTP
a rapid and long lasting increase in AMPA receptor component is followed by delayed but
also long-lasting potentiation of NMDA receptor component (Watt et al., 2004). It could
be that PSD-95, similarly to LTP increases AMPA receptor number, and NMDA receptors
follow AMPA receptors in order to restore AMPA/NMDA ratio of synapses. This way the
effect of PSD-95 on NMDA receptors would be indirect.
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Figure 5.23: A, Spine labeling of cell overexpressing PSD-95-HV:GFP. Scale bar 4.3 µm. B,
Distributions of AMPA and NMDA EPSC amplitudes for PSD-95-HV-infected and control cell
with bar graphs showing average AMPA and NMDA ratios.
We aimed to test whether PSD-95 effect on NMDA receptors is dependent on the effect on
AMPA receptors. In other words, would PSD-95 still lead to an increase in NMDA receptor
component under conditions where AMPA receptor component is not changed? To this end
we used the mutant version of PSD-95 where presumably interaction with stargazin and
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therefore with AMPA receptors is disrupted (Schnell et al., 2002). This mutant version of
PSD-95 has one point mutation in the PDZ domain 1 (H130V) and one in the PDZ domain
2 (H225V) that converts interaction of PSD-95 from a class I to a class II PDZ/ligand
interaction. We overexpressed this PSD-95 mutant (PSD-95-HV) and looked at AMPA and
NMDA currents.
The PSD-95-HV mutant showed localization to spines when overexpressed in CA1 cells
(Fig. 5.23A). Much to our surprise, PSD-95-HV still showed 3.0 ± 0.4-fold increase in AMPA
currents compared to control cell (Fig. 5.23B), suggesting that interaction of PSD-95 with
TARPs was not disrupted or PDS-95 interacted directly with AMPA receptors. We could
not exclude the possibility that PSD-95-HV interacted with a set of class II ligands (for
example, GluR2 or Ephrin B1), that could indirectly lead to increase in AMPA receptors
number. NMDA receptor component showed milder, 1.5 ± 0.2-fold increase.
Given that PSD-95-HV mutant has still an effect on AMPA currents, we could not use
this construct to dissociate PSD-95 effect on AMPA and NMDA currents.
5.2.5 Mechanism of PSD-95 effect on synaptic AMPA and NMDA receptors
5.2.5.1 Overexpression of PSD-95/PSD-93 chimeras
Next we asked the question whether the effect on synaptic receptors is limited to PSD-
95 or the other members of MAGUK family exhibit the similar effect. In the study of
Elias and colleagues, when PSD-93 was overexpressed in hippocampal organotypic slices,
infected cell showed approximately 2-fold increase in AMPA receptor component and no
effect in NMDA receptor component (Elias et al., 2006). We overexpressed PSD-93:GFP in
hippocampal slices and similarly to PSD-95, PSD-93 showed spine labeling (Fig. 5.24A).
Cells overexpressing PSD-93 showed an 1.6 ± 0.1-fold increase in AMPA currents and 1.6
± 0.2-fold increase in NMDA currents (Fig. 5.24B), indicating that the effect of PSD-93 on
synaptic currents was much milder compared to PSD-95.
What is the reason for the different effect of PSD-95 and PSD-93 on synaptic currents?
We compared the protein sequence of the two members of MAGUK family. Even though the
overall structure of PSD-95 and PSD-93 is similar, they differ in their N-termini preceding
the first PDZ domain (Fig. 5.25). We proceeded with exchanging the N-termini between
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Figure 5.24: A, Confocal image of CA1 cell overexpressing PSD-93:GFP showing spine local-
ization of PSD-93. Scale bar 6.8 µm. B, Distributions of AMPA and NMDA EPSC amplitudes
for PSD-93-infected and control cell with bar graphs showing average AMPA and NMDA ratios.
PSD-93 MFFACYCALRTNVKKYRYQDEDG-PHDHSLPRLTHEVRGPELVHVSEKNL
PSD-95 M--DCLCIVTT--KKYRYQDEDTPPLEHSPAHLPNQANSPP-V-------
PSD-93 SQIENVHGYVLQSHISPLKASPAPIIVNTDTLDTIPY---VNGTEIEYEF
PSD-95 -------------------------IVNTDTLEAPGYELQVNGTEGEMEY
PSD-93 EEITLERGNSGLGFSIAGGTDNPHIGDDPGIFITKIIPGGAAAEDGR...
PSD-95 EEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGR...
|------------------ PDZ1 ----------------------...
Figure 5.25: Protein sequence alignment of the PSD-95 and PSD-93 N-termini. The non-
homologous amino acids are shown in red. Three amino acids which are phosphorylated by
Cdk5 in PSD-95 and corresponding amino acids in PSD-93 are marked with squares.
PSD-95 and PSD-93 to test if the chimeras PSD-95(N93), i.e. PSD-95 with the N-terminus
of PSD-93 and PSD-93(N95), i.e. PSD-93 with the N-terminus of PSD-95, still exhibit
the observed effects on AMPA and NMDA currents as the wild types. Importantly, both
chimeras had normal spine localization as shown in figure 5.26.
PSD-95(N93) led to a 1.9 ± 0.2-fold increase in AMPA currents and no increase in NMDA
currents (1.1 ± 0.1, Fig. 5.27A). PSD-93(N95) chimera showed 2.5 ± 0.2-fold increase in
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PSD-95 (N93) PSD-93 (N95):GFP:GFP
Figure 5.26: Confocal images of CA1 cells overexpressing PSD-95(N93):GFP (scale bar 13.9
µ) and PSD-93(N95):GFP (scale bar 16.5 µm) showing spine localization of the chimeras.
AMPA receptor component and 1.7 ± 0.2-fold increase in NMDA receptor component (Fig.
5.27B). Effects of chimeras and PSD-95 and PSD-93 are summarized in the figure 5.27C.
The results we obtained for the chimeras were not conclusive regarding the protein domain
regulating the PSD-95 effect. PSD-95 with the N-terminus of PSD-93 had no effect on NMDA
currents, which was not the case in any other condition tested. The effect of PSD-95(N93)
on AMPA currents was similar to the effect of PSD-93. On the other hand, PSD-93 with
the N-terminus of PSD-95 showed much milder effect on AMPA currents than PSD-95 and
similar effect on NMDA currents as both wild types.
From these data we concluded that N-termini did not account alone for the effect of
PSD-95 and PSD-93 and they required cooperation with other protein domains.
5.2.5.2 Cdk5-phosphorylation mutants of PSD-95
Cdk5 phosphorylates T19, S25 and S35 of the PSD-95 N-terminus (Morabito et al., 2004).
Cdk5-dependent phosphorylation of PSD-95 was proposed to be a mechanism for regulating
the clustering of PSD-95: when phosphorylated PSD-95 multimerization and synaptic clus-
tering were reduced (Morabito et al., 2004). Inhibition of Cdk5 increases the binding of Src
to PSD-95 and that facilitates the phosphorylation of NR2B that stabilizes NR2B-containing
NMDA receptors on the cell surface (Zhang et al., 2008).
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Figure 5.27: AMPA and NMDA EPSC amplitude distribution of PSD-95(N93) (A) and PSD-
93(N95) (B) chimeras. C, Summary of the effect of overexpression of PSD-95, PSD-93, PSD-
95(N93)and PSD-93(N95).
The N-terminus of PSD-93 is not phosphorylated by Cdk5 (Fig. 5.25). We hypothesized
that phosphorylation of PSD-95 by Cdk5 may causes the differential effect of PSD-95 and
PSD-93 synaptic transmission. We mutated the phosphorylation sites in PSD-95 to the
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PSD-95 (T19A, S25A, S35A):GFP PSD-95 (T19D, S25D, S35D):GFP
Figure 5.28: CA1 cells overexpressing PSD-95(T19A,S25A,S35A):GFP (scale bar 7.5 µm)
and PSD-95(T19D,S25D,S35D):GFP (scale bar 9.6 µm) indicating that Cdk5-phosphorylation
mutants are localized to spines.
non-phosphorylatable PSD-95(T19A, S25A, S35A) and to the mutant that mimics phos-
phorylation, PSD-95(T19D, S25D, S35D). We expected that non-phosphorylated version of
PSD-95 may exhibit larger effect on AMPA and/or NMDA receptors by more pronounced
clustering of PSD-95 in the synapse and/or by stabilization of NMDA receptors at the cell
surface. Firstly, we checked whether the Cdk5 phosphorylation mutants had normal spine
localization. As shown in the figure 5.28, both mutants localized to spines.
PSD-95(T19A, S25A, S35A) did not show any larger effect on AMPA receptor component
compared to wild type PSD-95 and PSD-95(T19D,S25D,S35D) mutant (Fig. 5.29). In
fact, the effect on AMPA receptors was lower than for PSD-95 wild type (3.2 ± 0.4-fold,
Fig. 5.29A ) and similar to PSD-95(T19D,S25D,S35D) mutant which showed 3.5 ± 0.7-
fold increase (Fig. 5.29B). The effect of PSD-95(T19A,S25A,S35A) on NMDA current was
same as for wild type PSD-95 (1.8 ± 0.2, Fig. 5.29A), whereas PSD-95(T19D,S25D,S35D)
exhibited lower NMDA receptor increase (1.4 ± 0.2, Fig. 5.29B). A summary of these results
is shown in figure 5.29C.
From these data we concluded that PSD-95 effect on AMPA and NMDA receptor compo-
nent was not dependent on Cdk5 phosphorylation of the N-terminus of PSD-95.
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Figure 5.29: AMPA and NMDA EPSC amplitude distribution of posphorylation mutants
PSD-95(T19A,S25A,S35A) (A) and PSD-95(T19D,S25D,S35D) (B) chimeras. C, Summary of
the effect of overexpression of PSD-95 and the PSD-95 mutants on AMPA and NMDA currents.
5.2.5.3 Activity-dependence of PSD-95 effect
Development of glutamergic synapses requires spontaneous synaptic activity and NMDA
receptor activation (Zhu and Malinow, 2002). If PSD-95 shares the same mechanisms for
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Figure 5.30: AMPA and NMDA EPSCs from the slices incubated overnight with TTX (n=10
pairs) or APV (n=9 pairs)
promoting synapse development as synaptic activity, the prediction would be that the pres-
ence of TTX and APV in the slice would block the effect of PSD-95. To test this, we
incubated slices with TTX or APV and measured evoked EPSCs. TTX is a sodium chan-
nel blocker and prevents cells to fire action potentials, whereas APV is a NMDA receptor
antagonist.
In PSD-95-infected cells from the slices incubated with TTX AMPA receptor component
was increased 3.3 ± 0.7-fold and NMDA receptor component 2.1 ± 0.3-fold (Fig. 5.30).
Therefore, blocking of spontaneous activity in the slice from the time of infection did not
prevent PSD-95-mediated synaptic potentiation. Also in the slices incubated with APV,
PSD-95 overexpressing cells still showed both AMPA and NMDA currents enhancement
(AMPA: 4.7 ± 0.7-fold, NMDA: 2.0 ± 0.2-fold, Fig. 5.30), indicating that NMDA receptor-
mediated signaling was not necessary for the PSD-95 effect.
5.2.6 Rectification properties of PSD-95 overexpressing synapses
During the course of our study we observed that ratio of peak outward compound current
at +40 mV and peak inward current at -70 mV for infected cell was lower compared to
control cell. This suggested that PSD-95-overexpressing cells allowed only a small outward
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Figure 5.31: A, Representative traces of isolated AMPA currents at -70 mV and +40 mV
for the control (black traces) and PSD-95-infected cell (green traces). B, Rectification index
measured in control (n=28) and PSD-95-infected cells (n=28) (p<0.05, unpaired t-test).
current compared to control cells. The likely cause of the small current at positive po-
tentials is the presence of synaptic rectifying AMPA receptors. Namely, AMPA receptors
lacking edited GluR2 subunit, are Ca2+-permeable (CP-AMPA receptors) and exhibit in-
wardly rectifying I-V relationships (see also Introduction). The rectification is caused by
intracellular polyamines blocking the receptor pore at positive voltages. The ubiquitous
expression of GluR2 in principal neurons ensures that Ca2+-impermeable AMPA receptors
(CI-AMPA receptors) dominate synaptic transmission. However, recent studies showed that
CP-AMPA receptors are expressed in developing synapses of hippocampus (Ho et al., 2007).
Also, AMPA receptor redistribution, leading to an enrichment of CP-AMPA receptors in
the synapse, was shown to occur upon PICK1 overexpression (Terashima et al., 2004) and
cocaine administration (Bellone and Luscher, 2006).
We aimed to investigate whether overexpression of PSD-95 changed the rectification index
of the synapses. To this end, we measured isolated AMPA currents of PSD-95-infected and
control cells at -70 mV and +40 mV in the presence of APV. Rectification index was calcu-
lated as I+40/I−70. The cells overexpressing PSD-95 showed significantly smaller rectification
index than control cells (PSD-95: 0.3 ± 0.1; control: 0.6 ± 0.2, Fig. 5.31). This indicated
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Figure 5.32: Effect of 1µM PhTx on evoked AMPA EPSCs from PSD-95-infected cells (green)
and control cells (black). Plotted are averaged 1 min amplitudes normalized to the average
response obtained from the first 5 min of recordings before PhTx application. Each data point
represents mean±SEM of 5-11 cells recorded in pairs (p<0.05, paired t-test)
that PSD-95 overexpressing synapses had higher content of GluR2-lacking AMPA receptors
than control cells.
To further test for this, we used a GluR2-lacking AMPA receptors inhibitor, polyamine
philanthotoxin-433 (PhTx) (Koh et al., 1995), to block the rectifying Ca2+-permeable frac-
tion of AMPA receptors. After 10 minutes of 1µM PhTx application PSD-95-overexpressing
cells were significantly more sensitive to PhTx than control cell (Fig. 5.32). More specifi-
cally, AMPA currents of infected cells were 78 ± 7% of baseline (n=9), whereas the AMPA
currents of control cells exhibited even slight increase during the PhTx application, 115 ±
12% of the baseline (n=9).
Given the decreased rectification index and higher sensitivity to PhTx we suggest that
PSD-95 overexpression leads to an increase in GluR2-lacking receptors content in a synapse.
PSD-95 could either selectively mediate trafficking of rectifying receptors from the existing
pool or, similarly to PICK1, lead to recomposition of AMPA receptors.
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The goal of this study was to understand how the function and trafficking of AMPA receptors
are regulated. The focus was on the interaction of AMPA receptors with stargazin and PSD-
95. This study shows that AMPA receptors are functionally modulated by stargazin and
that receptors associated with stargazin have different pharmacological properties than the
receptors without stargazin. We found that antagonistic effect of CNQX, GYKI-53655 and
CP-465,022 on AMPA receptors was changed in the presence of stargazin.
We confirmed the finding that overexpression of PSD-95 dramatically increases the num-
ber of AMPA receptors in the synapse, and in addition, we observed an increase in NMDA
receptor number. We addressed the possible mechanisms of PSD-95 action and investigated
the role of Cdk5 kinase in regulating PSD-95 function. This study shows a novel finding
regarding the effect of PSD-95 on rectification properties of synaptic AMPA receptors, sug-
gesting that PSD-95 controls AMPA receptor synaptic localization in a subunit-dependent
manner.
6.1 Stargazin modulates AMPA receptors antagonism
TARPs function as auxiliary subunits of AMPA receptors. Similarly to auxiliary subunits of
voltage-gated channels, TARPs control the channel properties of AMPA receptors. Stargazin
slows AMPA receptor activation, deactivation and desensitization and increases the efficacy
of partial agonist kainate (Tomita et al., 2005; Priel et al., 2005; Turetsky et al., 2005).
Stargazin increases the efficacy of benzothiadiazides, and increases the potency of cycloth-
iazide on flop variants of AMPA receptors (Tomita et al., 2006). Stargazin association
reduces AMPA receptor affinity for spermine such that GluR2-lacking receptors display only
intermediate instead of complete rectification (Soto et al., 2007). Three other members of
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TARP family, γ-3, γ-4 and γ-8, regulate AMPA receptors in qualitatively similar manner,
although quantitatively they can show great heterogeneity (Cho et al., 2007; Milstein et al.,
2007).
We were interested in how stargazin affected the pharmacological properties of AMPA
receptors. To study the pharmacology of AMPA receptors, we used the Xenopus oocytes
expression system. This system has several advantages compared to other heterologous
expression systems. The oocytes have only few endogenous channels (for example Ca2+
-activated Cl− channels) and that permits a particular channel to be studied without con-
tamination currents from other channels. In addition, oocytes are large cells (about 1 mm in
diameter) and easy to handle. This system was used in other studies regarding the stargazin
effect on AMPA receptors (Tomita et al., 2004; Kott et al., 2007; Chen et al., 2000). We
investigated the effects of stargazin on the antagonism of competitive antagonist CNQX and
the allosteric inhibitors GYKI-53655 (GYKI) and CP-465,022 (CP).
6.1.1 Stargazin changes CNQX into partial agonist
We compared the sensitivity to CNQX of GluR1 in the presence and absence of stargazin.
We observed a higher IC50 for CNQX in the presence of stargazin than in the absence (Fig.
5.1B). During the course of our study the work of Menuz and colleagues was published
showing that CNQX acts as a partial agonist on AMPA receptors when they were associated
with TARPs (Menuz et al., 2007). We tested if we could observe the same phenomena in
our system. Indeed, when we measured dose-response curves of CNQX in the absence of
glutamate we could observe that CNQX activated AMPA receptors and elicited measurable
currents (Fig. 5.1C). These currents were much smaller than those obtained in the presence
of full agonist glutamate and reached 9 % ± 1 % of the currents evoked by 200 µM glutamate
(Fig. 5.1B). This effect explains our initial finding that stargazin lowers the affinity of CNQX.
More specifically, in the presence of stargazin CNQX competes with glutamate for binding
but evokes only small currents, so the outcome effect resembles inhibition.
How does stargazin affect binding of CNQX? When bound to the receptor, glutamate leads
to a conformational change within the ligand-binding domain (LBD) caused by rotation of
domain 2 toward the domain 1 that leads to subsequent linkers separation and pore opening.
74
6.1 Stargazin modulates AMPA receptors antagonism
Binding of full agonist, such as glutamate, induces maximal domain closure, whereas CNQX
in the absence of TARP led to a partial domain closure (Menuz et al., 2007) (Fig.3.3B, see
also Introduction). Association of stargazin could either enhance this domain closure by
interacting directly with LBD or it facilitates the transduction of domain closure to channel
opening by interacting with the linker domains of the receptor. Our data on stargazin effect
on GYKI- and CP-insensitive mutants (Fig. 5.5, see below) strongly suggests that stargazin
interacts with the linker domains of the receptor.
6.1.2 Stargazin changes the antagonism of GYKI and CP
We next focused on allosteric inhibitors of AMPA receptors, GYKI and CP. In contrast to
the effect on CNQX, co-expression of stargazin increased the affinity of GluR1 homomers for
GYKI and CP (Fig. 5.3A and B). The effect on CP binding was milder compared to GYKI.
What can explain the difference in the stargazin effect on these two drugs? Menniti and
colleagues showed that there is a single binding site for CP on AMPA receptor subunit and
that site overlaps with the binding site of GYKI-52466 (Menniti et al., 2000). In addition,
Balannik and colleagues showed that in the absence of stargazin the binding sites of these
two drugs are located in the linker domains and partly overlap (Balannik et al., 2005).
Nevertheless, association of stargazin affected the inhibition by GYKI and CP to a different
extent. This could be explained by the structural differences of GYKI and CP (Fig. 3.4).
It is still not known what part of GYKI and CP binds directly to the receptors. The
methylcarbamyl group at the N-3 position of GYKI-53655 makes it more potent inhibitor
than its analog GYKI-52466 (Donevan et al., 1994). The increased affinity of the N-3-
substituted analogs related to their increased binding and decreased unbinding rates. The
presence of this group could also be important for the increased efficacy of GYKI in the
presence of stargazin. Alternatively, allosteric effect of stargazin binding might lead to a
formation of additional binding site for GYKI, but not for CP. We cannot exclude the
possibility that GYKI but not CP might interact directly with stargazin.
Interestingly, Mayer and colleagues reported in one of the first studies investigating the
mechanisms of GYKI that native AMPA receptors expressed from polyA+ mRNA revealed
greater sensitivity to GYKI than receptors generated by expression of recombinant AMPA
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receptors. They suggested that this might be explained by either an interaction with an
unidentified accessory protein or a novel receptor subunit (Partin et al., 1996). Our data
suggest that the reported difference might be caused by the associated TARP.
6.1.3 Increased GYKI sensitivity is independent from desensitization
In order to obtain larger glutamate-evoked currents we performed all recordings in the pres-
ence of TCM, a positive AMPA receptor modulator similar to CTZ. Some earlier studies
suggest that CTZ and GYKI bind in a competitive manner at a common binding site of
the receptor, and that GYKI might exhibit its effect by promoting the desensitization of
AMPA receptors (Palmer and Lodge, 1993; Zorumski et al., 1993). In order to exclude the
interference of TCM on stargazin effect, we measured GYKI dose-response curves in the
absence of TCM. Under this condition we still observed lower IC50 of GYKI in the presence
of stargazin arguing that effect of stargazin on GluR1 affinity for GYKI is independent of
desensitization (Fig. 5.4A). However, in case of the non-desensitizing GluR1LY mutant, the
effect of stargazin on GYKI antagonism was abolished. In the GluR1LY mutant the aromatic
side chain projects into the domain 1 of a partner subunit, increasing the affinity for dimer
formation more that 105-fold (Weston et al., 2006). Conformation of LY mutant might be
more rigid, occluding the effect of stargazin. This is also suggested by the finding that LY
mutation perturbed stargazin action on glutamate-evoked currents (Tomita et al., 2007).
Balannik and colleagues suggested that manipulations, which reduce AMPA receptor de-
sensitization, decrease the inhibitory effect of GYKI and CP (Balannik et al., 2005). They
measured 10-fold higher IC50 of GYKI for GluR3 homomers in the presence of CTZ than in
the absence. In the presence of stargazin, we observed only a moderate difference of GYKI
IC50 in the presence of TCM (-TCM 28 µM; +TCM 38.5 µM). Surprisingly, in the absence
of stargazin we saw the opposite effect of TCM: GYKI potency was lower in the absence of
TCM (≈200 µM) than in the presence of TCM (≈100 µM). Is TCM/CTZ effect on GYKI
potency different for GluR3 homomers compared to GluR1 homomers? Although this possi-
bility does not seem very likely, some subunit-dependence of CTZ action has been reported:
CTZ shifted the GYKI-52466 inhibition curve to the right in heteromeric AMPA receptors
but not in GluR1 and GluR4 homomers (Johansen et al., 1995). The authors explained
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this effect as the lower sensitivity of GluR2-lacking receptors for GYKI-52466 in the absence
of CTZ. At present, the allosteric interaction between CTZ/TCM and GYKI and possible
AMPA receptor subunit-dependence of this interaction remains poorly understood.
6.1.4 Stargazin restores sensitivity of insensitive mutants
Using receptor mutagenesis, Ballanik and colleagues found that GYKI and CP bind at the
S1-M1 and S2-M4 linkers region, thereby disrupting the transduction of agonist binding to
channel opening (Balannik et al., 2005). The authors used the Xenopus heterologous system
to overexpress GluR subunits in the absence of stargazin. Since there is no evidence for native
”TARP-less” AMPA receptors, we reinvestigated this finding by co-expressing stargazin with
previously described GYKI- and CP- mutants. Overexpression of stargazin restored the
sensitivity to GYKI of GluR1GYKI , whereas GluR1CP co-expressed with stargazin was only
mildly blocked by higher concentrations of CP (Fig. 5.5A and B).
There are at least two possible mechanisms of how the introduced mutations lead to the
receptor insensitivity: one possibility is that GYKI cannot bind anymore to the receptors
and the other is that binding of GYKI is intact but the transduction of LBD conformational
change to the pore opening is not prevented by GYKI binding. How could stargazin recover
the sensitivity of the ”insensitive” mutants? By an allosteric interaction with the linker
domains, stargazin could create a new binding site for GYKI. Alternatively, in the presence
of stargazin binding of GYKI might block the pore opening of the ”insensitive” mutants.
Based on these results, we concluded that stargazin interacts with the linker domains of the
receptor rather than with the LBD.
We were not able to test GYKI sensitivity of GluR2GYKI and GluR2WT in the absence of
stargazin due to the low expression level, but we could see that GluR2GYKI co-expressed
with stargazin was sensitive to GYKI in a similar manner that GluR2WT was, implying that
qualitatively stargazin effect was not subunit-dependent.
6.1.5 Ectodomain of stargazin modulates antagonist affinity
Different domains of stargazin are involved in trafficking of receptors and changing the chan-
nel properties: the cytoplasmic tail of stargazin determines receptors trafficking, whereas
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the ectodomain controls channel properties (Tomita et al., 2005). Tomita and colleagues de-
signed a chimeric stargazin protein with the first ectodomain replaced with the one from γ-5
(Ex1 chimera) and this construct had no effect on desensitization and deactivation of AMPA
receptors (Tomita et al., 2005). Interestingly, Ex1 did not change CNQX into partial agonist
when we co-expressed it with GluR1. It also did not have any effect on CNQX inhibition
dose-response curves (Fig. 5.2A and B). In case of GYKI inhibition, both GluR1WT and
GluR1GYKI when co-expressed with Ex1 were less sensitive to GYKI than without stargazin.
Importantly, Ex1 still trafficked the receptors to the surface, since the currents were much
larger than in the absence of Ex1.
This finding suggests that the first ectodomain of stargazin is involved in the process of
GluR1 inhibition. This is important finding for understanding the pharmacology of AMPA
receptors and also offers a new approach for the therapeutic drug design focusing on the
regulation of TARP ectodomain-AMPA receptor interaction.
6.1.6 Insensitive mutants show altered glutamate dose-response curves
During the course of our experiments we observed that mutants of GluR1 showed lower
currents than wild type receptors when expressed in oocytes. Although our experiments
were design to monitor inhibition of insensitive mutants, we could not exclude the possibility
that mutant forms of GluR1 had other receptor properties altered. Therefore, we measured
the glutamate dose-response curves of GluR1WT and the insensitive mutants. We observed
a 2.7-fold decrease in the EC50 for glutamate of GluR1 in the presence of stargazin (Fig.
5.8). In similar studies, the EC50 for glutamate was decreased 3.7-fold (Priel et al., 2005)
and 2-fold (Yamazaki et al., 2004) when stargazin was co-expressed with GluR1 in oocytes.
However, we could not observe the same effect of stargazin on insensitive mutants: EC50 of
GluR1GYKI was only modestly affected by co-expression of stargazin and EC50 of GluR1CP
was same in the presence and absence of stargazin. Interestingly, the mutants had higher
EC50 already when expressed alone. The linkers separation upon glutamate binding in these
mutants might be greater than in the wild type and perhaps could not be further enhanced
by stargazin.
There are some examples in the literature where point mutations in GluR subunits led
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to an increased potency of glutamate. For example, LY mutation in GluR subunits that
renders AMPA receptors non-desensitizing showed lower EC50 value than wild type GluR
(Stern-Bach et al., 1998; Armstrong et al., 2003). Similarly, non-desensitizing GluR6 Y490C
L752C mutant had 20-fold lower EC50 than wild type GluR6 (Weston et al., 2006). Not only
mutations in LBD could lead to increased potency of glutamate. Lurcher mutation located
in a hydrophobic region of the M3 domain of GluR subunit showed increased affinity for
glutamate and reduced desensitization (Klein and Howe, 2004). Interestingly, stargazin has
no effect on glutamate EC50 of both LY and Lurcher mutants (Priel et al., 2005; Tomita
et al., 2007).
6.1.7 Insensitive mutants show reduced surface expression
Stargazin greatly increased glutamate-evoked currents from Xenopus oocytes when co-injec-
ted with limited amount of GluR1 (Tomita et al., 2005). Importantly, this increase was
shown to be the effect of both increased number of receptors at the surface and enhanced
glutamate efficacy. We measured a 4.2-fold increase in surface expression of GluR1 when co-
expressed with stargazin (Fig. 5.9A), which is similar enhancement by stargazin Yamazaki
and colleagues observed in HEK cells: 4.1-fold increase for GluR1 and 4.3-fold increase
for GluR2 (Yamazaki et al., 2004). The mutants GluR1GYKI and GluR1CP were expressed
much less on the oocytes surface in the absence of stargazin compared to wild type. Stargazin
potentiation of surface expression was still present (8.5-fold increase for GluR1GYKI and 9.5-
fold increase for GluR1CP ) but the expression levels were still lower than when GluR1 was
expressed alone.
AMPA receptors as multimeric proteins are subject to a quality-control system in the
ER which verifies whether receptors are folded and assembled properly. The subunits have
retention signals that can be masked by heteromeric assembly. For example, the Q/R editing
site in the re-entrant loop of GluR2 subunit was shown to be the retention signal. The
edited GluR2 could exit the ER only when assembled with other subunits (Greger et al.,
2002). There is the evidence that functionality of the receptors can be also verified in the
ER. GluR6 mutants with blocked desensitization as well as non-desensitizing GluR2 LY
mutant are retained in the ER, pointing to the functional check point in the ER (Priel
79
6 Discussion
et al., 2006; Greger et al., 2006). Similarly, mutations that eliminate glutamate binding in
kainate receptors promote the retention of these receptors (Mah et al., 2005; Valluru et al.,
2005). Our observation that GluR1GYKI and GluR1CP were also largely retained in the
intracellular compartments in the absence of stargazin, suggests further that only receptors
with non-altered function can be exported to the surface.
How is the function of the receptors monitored in the ER? What is the quality control
mechanism that prevents non-desensitizing receptors and receptors that cannot bind glu-
tamate to exit the ER? Numerous quality control mechanisms exist to retain ER-resident
proteins and immature, monomeric, or misfolded proteins. However, most of the mentioned
mutations do not lead to a gross change in the receptor conformation. The glutamate is con-
stantly present in the ER implying that oligomeric GluRs would naturally exist in a bound
conformation (Meeker et al., 1989). The binding of glutamate lead to the channel opening
and subsequent desensitization of the receptors. Priel and colleagues suggest that glutamate
binding in the ER might be needed for the presentation of the desensitized conformation to
quality control machinery. The quality control machinery could recognize structural signals
in the LBD, either the specific motif that is exposed or masked at the desensitized state or
global conformational change of the receptor (Priel et al., 2006). In that sense, the GluR1
mutants we used in our study might have altered gating that would lead to their impaired
trafficking.
Unlike kainate receptors, AMPA receptors interact with TARPs, therefore the mechanism
of their exit from the ER may have some unique features. The recent study shows that
GluR4 that cannot bind glutamate can be exported to the surface when co-expressed with
stargazin (Coleman et al., 2009). It seems that both glutamate and stargazin make additive
contributions to structural stability of AMPA receptor LBD and thereby promote their exit
from the ER.
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6.2 PSD-95 regulates synaptic function in hippocampal neurons
Members of MAGUK family are scaffolding proteins present at excitatory synapses. PSD-
95, the prototypical member of the family, binds to the C-terminus of NR2 subunits of
NMDA receptors and cluster them on the membrane surface (Kornau et al., 1995). This
proposed that PSD-95 might localize NMDA receptors to the synapse. Since this finding
many studies focused on the role of PSD-95 in synaptic function and clear conclusion that
emerged from these studies was somewhat surprising: PSD-95 is necessary for synaptic
trafficking of AMPA receptors. However, some differences in the observations obtained from
different labs accompanied this finding. The role of PSD-95 in the localization of NMDA
receptors, as well as the possible role in the presynaptic function have not been established
yet.
We used viral overexpression to increase the level of PSD-95 in hippocampal neurons
and monitored the consequences of this manipulation on synaptic function. Our study
supports the model in which PSD-95 regulates the number of synaptic AMPA receptors
but in addition suggests an effect on NMDA receptor number as well as on AMPA receptor
subunit-composition.
6.2.1 PSD-95 overexpression enhance both AMPA and NMDA currents
Virally overexpressed PSD-95 localized to spines as it showed punctated staining (Fig. 5.12).
Synaptic currents of infected neurons were largely affected: AMPA currents were increased
4.5± 0.4-fold, whereas NMDA currents were increased 1.8± 0.1-fold compared to a neighbor-
ing control cell (Fig. 5.13). The effect of PSD-95 on AMPA receptor-mediated transmission
was already reported in several studies (Schnell et al., 2002; Stein et al., 2003; Beique and
Andrade, 2003; Ehrlich and Malinow, 2004). Biochemical experiments showed that PSD-95
increased the number of AMPA receptors rather than changing intrinsic biophysical proper-
ties of AMPA receptors (El-Husseini et al., 2000). PSD-95 was found to be a critical factor
driving AMPA receptors into synapse during LTP and experience-driven synaptic strength-
ening (Stein et al., 2003; Ehrlich and Malinow, 2004). All these data suggest that PSD-95
is necessary for synaptic trafficking of AMPA receptors.
Does PSD-95 traffic AMPA receptors in native synapses or the increase in AMPA receptors
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number we and others observed was overexpression artifact? Studies of PSD-95 and PSD-93
knock-out mice reported normal AMPA and NMDA currents in these mice (Migaud et al.,
1998; Elias et al., 2006). This suggests a large redundancy and functional compensation
between the members of MAGUK family. When deleted in the germ line, particular MAGUK
member can be replaced by other members. When shRNA for either PSD-95 or PSD-93
was used acutely in hippocampal neurons containing fully mature synapses, basal AMPA
receptors transmission was reduced 50% (Elias et al., 2006), proving that MAGUKs are
necessary for the synaptic localization od AMPA receptors.
The role of PSD-95 in trafficking and synaptic localization of NMDA receptors is less
established. PDZ-interaction of NMDA receptors was shown to be important for masking
their retention signal and subsequent exit from the ER (Standley et al., 2000). SAP102
was shown to be involved in the NMDA receptors delivery to the cell surface through an
interaction with the exocyst complex member, Sec8 (Sans et al., 2003). Transgenic mice
expressing NR2A with deleted C terminus showed an absence of NMDA receptors from the
synapse, but receptors were expressed at the extrasynaptic sites (Steigerwald et al., 2000).
This finding resembles the study of Schnell and colleagues where stargazin overexpression
did not lead to an increase in synaptic AMPA currents (Schnell et al., 2002), suggesting that
the sheer increase in the receptor number is not sufficient for synaptic potentiation. Instead,
the number of synaptic slots is the limiting factor for the postsynaptic strength. All these
initial studies pointed to the model that PDZ-interaction of NMDA receptors was necessary
for their synaptic localization and MAGUK members were the likely candidates to control
this synaptic trafficking.
Given the data described above, it was surprising that in previous studies the overex-
pression of PSD-95 in the organotypical hippocampal slices did not lead to an increase in
NMDA currents (Schnell et al., 2002; Stein et al., 2003). Additional mechanisms controlling
the NMDA receptor synaptic number were suggested. We did observe an increase in NMDA
receptors currents upon overexpression of PSD-95 (Fig. 5.13 and 5.18) that we could not
explain by a change in a subunit composition of NMDA receptors (Fig. 5.22), nor as an
effect of different experimental conditions used (Fig. 5.17). We hypothesized that this effect
might not be a direct effect of PSD-95 on NMDA receptors but rather indirect, as an gross
increase in AMPA receptor number would eventually lead to the insertion of NMDA recep-
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tors. Since we were not able to abolish the effect of PSD-95 on AMPA receptors using class
II PSD-95 mutation (PSD-95-HV, Fig. 5.23), we could not test whether PSD-95 would still
drive NMDA receptors into synapses without a ”pre-increase” in AMPA receptors number.
Taken together, our data suggest that increased level of PSD-95 in neurons creates addi-
tional synaptic slots enabling more receptors to participate in the synaptic transmission. It
is still not clear whether PSD-95 only provides slots or interacts with the AMPA receptor-
TARP complexes and NMDA receptors already outside the synapse. In case of the first
possibility, PSD-95 could increase the number of slots for both AMPA receptors and NMDA
receptors, but since the NMDA receptors are less mobile and/or available at the extrasy-
naptic sites than AMPA receptors, the probability that they get captured in the PSD is
lower.
6.2.2 PSD-95 does not change glutamate release probability
PSD-95 interacts with neuroligin, a transmembrane protein that binds to presynaptic β-
neurexins. It was reported that PSD-95 modulated presynaptic release probability via this
interaction (Futai et al., 2007). The presynaptic locus of PSD-95 effect would explain both
AMPA and NMDA currents enhancement that we observed. We performed several experi-
ments addressing the release probability in the cells overexpressing PSD-95. We could not
observe any difference between non-infected and infected cells neither in paired-pulse ratio
(Fig. 5.19) nor in the kinetics of MK-801 block (Fig. 5.20). The effect of PSD-95 on NMDA
receptors did not show any sensitivity to extracellular Ca2+ concentration as NMDA current
enhancement was largely constant in all of the concentration tested (Fig. 5.21). Therefore,
our data argue for no change in release probability in the cells overexpressing PSD-95.
PSD-95 was suggested to be involved in maturation of presynaptic terminals in disso-
ciated hippocampal neurons as it enhanced presynaptic cluster size and FM4-64 staining
(El-Husseini et al., 2000). Hippocampal neurons cultured for 21 days overexpressing PSD-95
had larger and more numerous spines (El-Husseini et al., 2000). What could be the mecha-
nism mediating the possible effect of PSD-95 on synapse formation and number? One of the
first step in the synapse formation is the assembly of the presynapse. Discrete pre-assembled
packets of presynaptic active-zone are rapidly transported to the site of axodendritic contact
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(Ahmari et al., 2000). The assembly sequence of the postsynaptic part is less clear. Most
of the studies suggested that PSD-95 is one of the first protein recruited to the synapse.
PSD-95 and GKAP (guanylate kinase domain-associated protein) both clustered at synaptic
sites in young cultured hippocampal neurons several days before NMDA and AMPA recep-
tors and shortly after the formation of presynaptic specializations (Rao et al., 1998). The
filopodia and spines of young cultured cortical neurons bearing PSD-95:GFP clusters were
significantly more stable, suggesting that decreased mobility of dendritic filopodia during
the development is caused by the presence of PSD-95 clusters (Prange and Murphy, 2001).
In contrast, Washbourne and colleagues found that discrete clusters of NMDA receptors
were present in the dendrites from young cortical neurons before synapse formation and
that these NMDA receptors clusters were recruited to new synapses within minutes after
presynaptic contacts (Washbourne et al., 2002). Surprisingly, recruitment of NMDA receptor
clusters could either precede or overlap with PSD-95 recruitment.
How could overexpression of PSD-95 lead to the increased spine size and number? By
providing more slots in the postsynaptic density and insertion of more synaptic receptors,
PSD-95 could lead to parallel expansion of the presynaptic terminal and release machinery,
for example vesicle pool. The presence of more PSD-95 in the cell could lead to stabi-
lization of the initial contacts made by the dendritic filopodia which would result in more
spines. Multimerization of SAP97 was associated with increased stability of SAP97 in spines
(Nakagawa et al., 2004). It could be that high amount of PSD-95 protein caused by viral
overexpression led to more prominent mulitimerization of PSD-95 which would result in
lower spine turnover, and subsequently more spines and higher EPSC amplitudes.
We did not observe a change in release probability in infected cells, but we could not
exclude that overexpression of PSD-95 led to an increased number of spines and/or lower
turnover of existing spines. In that case, an increase in both AMPA and NMDA currents
must be expected.
6.2.3 Overexpression of PSD-93 shows modest effect on synaptic currents
We observed much milder effect of PSD-93 overexpression on synaptic currents compared
to PSD-95 overexpression. Cells overexpressing PSD-93 showed 1.6 ± 0.1-fold increase in
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AMPA currents and 1.6 ± 0.2-fold in NMDA currents (Fig. 5.24). What could account for
the different effect of different MAGUK members?
Beside the PSD-95 and PSD-93, overexpression of SAP102 also led to the selective increase
in AMPA EPSCs (Schnell et al., 2002). In PSD-95/PSD-93 double knockout mice SAP102
expression was upregulated and accounted for the remaining AMPA receptor-mediated cur-
rent (Elias et al., 2006). However, acute knockdown of SAP102 with shRNA did not alter
the basal synaptic transmission indicating that SAP102 is not necessary for the receptors
localization in mature synapses (Elias et al., 2006).
The role of the fourth member of MAGUK family, SAP97 is less well understood. SAP97
is distinct from the other MAGUK members in a way that interacts directly with the C-
terminus of GluR1 (Leonard et al., 1998) and has no palmitoylation signal necessary for
the synaptic localization. Schnell and colleagues did not observe any effect of SAP97 over-
expression on AMPA and NMDA currents, but when they overexpressed a chimera where
the PSD-95 palmitoylation motif was inserted on SAP97 both AMPA and NMDA compo-
nents were increased (Schnell et al., 2002). In contrast, other studies showed that SAP97
overexpression in hippocampal slices led to an increase in AMPA EPSCs (Nakagawa et al.,
2004). Using the negative-stain electron microscopy, the authors showed surprisingly differ-
ent shapes of monomeric PSD-95 and SAP97, and whereas PSD-95 was mainly monomeric
SAP97 tended to dimerize (Nakagawa et al., 2004). In addition, it was shown that the
C-terminal of GluR1 was essential for bringing SAP97 to the plasma membrane, where it
acted to promote dendrite growth (Zhou et al., 2008). The difference in the shape and mul-
timerization between SAP97 and PSD-95 suggests that even though the molecular structure
of the MAGUK proteins may be the same, they can serve different roles as scaffolds. Also
given the role of SAP97 in dendrite growth, it could be that some of the MAGUKs have
additional roles in neurons.
It was shown previously that PSD-95 and PSD-93 control the number of AMPA receptors
at non-overlapping subsets of excitatory synapses (Elias et al., 2006). The shRNA knockdown
of both PSD-95 and PSD-93 led to the same (≈50%) decrease in AMPA EPSC, although the
overexpression of PSD-93 gave ≈2-fold increase in AMPA EPSC, less than it was observed
for PSD-95 (Elias et al., 2006; Schnell et al., 2002). PSD-95 and PSD-93 differ in their
N-terminal sequence (Fig. 5.25). From the data obtained for PSD-95/PSD-93 chimera-
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overexpression we could conclude that the N-terminus did not solely account for the PSD-95
and PSD-93 effect, so the downstream protein parts also take part in determining MAGUKs
specificity. The milder PSD-93 effect on basal synaptic transmission we observed could be
caused by a lower protein level expression of PSD-93, different potential of PSD-93 to make
synaptic slots or smaller population of synapses affected by PSD-93 overexpression.
6.2.4 Cdk5-dependent phosphorylation does not control the effect of PSD-95
Cdk5 is a serine-threonine kinase with diverse functions both in normal and pathological
processes in mammalian CNS and it has been implicated in the processes of learning and
memory. Genetic deletion of Cdk5 causes perinatal lethality with severe defects in cortico-
genesis and neuronal positioning (Ohshima et al., 2005). Conditional Cdk5 knock-out adult
mice had normal AMPA receptor-mediated fields and increased NMDA receptor-mediated
transmission due to a direct effect of Cdk5 on NR2B-containing NMDA receptors degrada-
tion (Hawasli et al., 2007). Namely, deletion of Cdk5 reduced degradation of NR2B-receptors
by calpain, leading to improved spatial memory and lower threshold for LTP compared to
the wild type (Hawasli et al., 2007).
The N-terminus of PSD-95 contains consensus phosphorylation sites for Cdk5 kinase. The
Cdk5-phosphorylation status of PSD-95 regulates its clustering in the synapse (Morabito
et al., 2004). A non-phosphorylatable mutant version of PSD-95 had bigger cluster size
compared to wild type. Also cultured cortical neurons from Cdk5 knock-out mice showed
larger clusters of PSD-95 compared to the wild type cells (Morabito et al., 2004). Cdk5 was
also reported to have an indirect effect on NR2B-containing NMDA receptors via PSD-95
phosphorylation, where phosphorylation of PSD-95 affected NR2B receptors internalization
(Zhang et al., 2008). We tested if the non-phosphorylatable mutant led to higher AMPA
and NMDA currents compared to wild type, but we could not observe such an effect (Fig.
5.29A). Also PSD-95 mutant that mimicked the Cdk5 phosphorylation did not show any
significantly different effect on AMPA and NMDA currents compared to wild type PSD-95
(Fig. 5.29). Importantly, both mutants localized to spines (Fig. 5.28).
What could explain the absence of differential effects of PSD-95 phosphorylation mutants?
Both above described effects of Cdk5 on PSD-95 were demonstrated in dissociated neuronal
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cultures and it could be that the phosphorylation of PSD-95 does not affect the clustering in
more physiological preparations, such as cultured slices. On the other hand, Cdk5-mediated
phosphorylation of PSD-95 might play a role in PSD-95 clustering only during the period of
synaptogenesis and not once synapses are established. Alternatively, it could be that PSD-95
cluster size does not necessarily affect the synaptic strength.
6.2.5 PSD-95 effect on synaptic currents is not activity-dependent
Spontaneous activity of neurons is of great importance for their normal development. Chan-
ges in network activity are sensed by the neurons and they response by triggering the activity-
dependent signaling. We hypothesized that some of these activity-dependent mechanisms
might be important for PSD-95 to exhibit its effect. We incubated slices in TTX, which
prevented the cells to fire the action potentials, but PSD-95 still enhanced AMPA and NMDA
EPSCs (Fig. 5.30). The effect on AMPA currents was somewhat lower in the presence of
TTX, which could be explained by the upregulated insertion of AMPA receptors in the
presence of TTX (”synaptic scaling”) therefore occluding the effect of PSD-95. Namely,
when the activity of neurons is chronically blocked by prolonged incubation with TTX there
is an upregulation of the number of synaptic AMPA receptors. This process is believed to be
a homeostatic mechanism evolved to compensate for the decreased excitation of the neuron.
Activation of NMDA receptors during the spontaneous activity and subsequent influx of
Ca2+ plays also a role in development of neuronal circuits. For example, NMDA receptors ac-
tivated during miniature synaptic events, actively inhibit dendritic GluR1 synthesis, tonically
suppressing the synaptic expression of GluR1 homomers (Sutton et al., 2006). Importantly,
NMDA-induced internalization of AMPA receptors was shown to be mediated by NMDA
receptor-activation dependent PSD-95 ubiquitination (Colledge et al., 2003). Pharmacologi-
cal blockade of NMDA receptors in hippocampal slices did not affect synapse formation and
dendritic spine growth but did increase the motility of spines (Alvarez et al., 2007). When
we blocked NMDA receptors by incubating slices by APV, both AMPA and NMDA currents
were enhanced similarly to the control conditions (Fig. 5.30). This result suggests that Ca2+
influx through NMDA receptors is not necessary for the PSD-95 effect on synaptic currents.
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6.2.6 PSD-95 overexpression and AMPA receptor-subunit composition
AMPA receptors in hippocampus are usually composed of GluR2/3 and GluR1/2 (Wenthold
et al., 1996). The presence of edited GluR2 subunit determines the key properties of AMPA
receptors, such as Ca2+-permeability and rectification. Unlike interneurons which have sig-
nificant portion of GluR2-lacking receptors, pyramidal neurons express GluR2-lacking recep-
tors only early in the development (Pickard et al., 2000). However, some studies suggested
that pyramidal neurons may have a significant pool of GluR2-lacking receptors that might
get incorporated in the synapse under certain circumstances (Kumar et al., 2002; Ju et al.,
2004; Terashima et al., 2004). A recent study shows that LTP induction in CA1 hippocam-
pal neurons causes the rapid incorporation of GluR2-lacking AMPA receptors at synapses,
but these are only present transiently and are replaced by GluR2-containing receptors after
20 min of LTP expression (Plant et al., 2006).
PSD-95 overexpression occludes LTP implying that they utilize the same cellular mech-
anism for regulating the synaptic strength (Stein et al., 2003). We tested whether PSD-95
overexpression also inserted GluR2-lacking receptors into the synapses. Indeed, we observed
significant decrease in the rectification index in cells overexpressing PSD-95 (Fig. 5.31). The
increased content of GluR2-lacking receptors was further confirmed by partial sensitivity of
infected cells to PhTx (Fig. 5.32).
The remaining question is where the GluR2-lacking receptors come from and how PSD-95
selectively inserts them into a synapse. It could be that there is a pre-existing pool of GluR2-
lacking receptors but it can be recruited to the synapses only under certain conditions, for
example during LTP (Plant et al., 2006). PSD-95 may trigger the same signaling mechanisms
in neurons as LTP which would result in an increased portion of synaptic GluR2-lacking
receptors. The time point of developmental switch from GluR2-lacking to GluR2-containing
AMPA receptors may vary between different preparations and different culturing conditions.
In acute cortical slices this switch occurred around the postnatal day 16 (Kumar et al.,
2002) and in dissociated hippocampal cultures around 14 DIV (Pickard et al., 2000). We
performed our experiments in slices that corresponded to the postnatal day 14-18, indicating
that some CP-AMPA receptors might still be present in the CA1 neurons.
Another exciting possibility is that PSD-95 may lead to a recomposition of AMPA re-
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ceptors. A change in the AMPA receptor subunit composition has been already observed
under following conditions. PICK1, a protein that regulates surface expression of GluR2
subunit, was overexpressed in acute hippocampal slices from 7-12 days old rats and 20-48
hours later the GluR2 content in the synapses was decreased without the change in GluR1
levels (Terashima et al., 2004). This effect of PICK1 on GluR2 was accompanied with the
change in the rectification index. AMPA receptor redistribution dependent on PICK1-GluR2
interaction was also observed in neurons of ventral tagmental area upon cocaine administra-
tion (Bellone and Luscher, 2006). Testing whether the effect of PSD-95 on AMPA receptor
rectification is sensitive to PICK1-GluR2 interaction could answer the question of the mech-
anism behind the increased portion of CP-AMPA receptor in the PSD-95 overexpressing
cells.
Ju and colleagues observed that activity-block in cultured neurons led to an increased
dendritic synthesis of GluR1 but not GluR2 (Ju et al., 2004). PSD-95 overexpression might
affect de novo dendritic synthesis of GluR1 subunit, resulting in higher content of GluR2-
lacking receptors in the synapses.
GluR2 subunit is critical in determining mammalian AMPA receptor function. Thus,
understanding the mechanisms that regulate abundance of GluR2-lacking AMPA receptors
is of great importance. Emerging role of PSD-95 as one of these mechanisms might be of
particular significance.
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6.3 Conclusions and Outlook
In my thesis I addressed several aspects of AMPA receptor physiology. More specifically, I
investigated how AMPA receptor antagonism is modulated by stargazin, the AMPA receptor
auxiliary subunit of the TARP family, and how AMPA receptor synaptic localization is
regulated by PSD-95, the main scaffolding protein of excitatory synapse.
In the first part of my thesis I assessed the effect of stargazin association on the inhibition
of AMPA receptors by commonly used antagonists CNQX, GYKI-53655 and CP-465,022.
To that end, I employed the Xenopus oocyte expression system to express GluR1 AMPA
receptor subunit with and without stargazin. I found that GluR1 homomers associated with
stargazin had different pharmacological properties than receptors without stargazin. In ad-
dition, my study reveals differential effect of stargazin on competitive and non-competitive
inhibitors. Co-expression of stargazin decreased the sensitivity of AMPA receptors to com-
petitive antagonist CNQX. In fact, CNQX was a partial agonist and not an antagonist of
AMPA receptors in the presence of stargazin. In contrast, stargazin increased sensitivity of
AMPA receptors to a non-competitive inhibitor GYKI-53655 and had the same, but milder,
effect on another non-competitive inhibitor, CP-465,022. Interestingly, stargazin recovered
the sensitivity of previously described GYKI-53655-insensitive mutant. Given that the muta-
tions of this mutant are located in the linker domains of AMPA receptor subunit, this finding
strongly suggests that stargazin interacts with the linker domains of the receptors, instead,
or in addition, to the ligand-binding domain as it was previously suggested. The insensitive
mutant showed also impaired surface trafficking to the membrane surface, supporting the
idea that only receptors without altered function are exported to the cell surface.
This study also shows that extracellular domain of stargazin regulates the AMPA receptor
antagonism. That finding is important for both understanding the AMPA receptor-TARP
interaction and future therapeutic approach when AMPA receptor blockers are concerned.
Another important implication of these study is that stargazin co-expression is necessary
when pharmacology of AMPA receptors is studied in the heterologous systems, given that
probably all native AMPA receptors are associated with TARPs.
There are still many open questions regarding the interaction of AMPA receptors with
TARPs. For instance, the number of TARP molecules that bind to a AMPA receptor
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tetramer is not known. It would be interesting to see whether this number is constant over
the whole population of AMPA receptors, or is dynamically regulated, for example in the
receptor subunit-dependent manner. Another open question is whether all AMPA receptors
are associated with TARPs. To date, there is a lack of evidence for ”TARP-less” AMPA
receptors, but the possibility that certain populations of neurons or even subsets of synapses
of the same neuron might not have TARPs, cannot be excluded.
In the second part of my thesis I focused on PSD-95, the most studied synaptic scaffolding
protein of the MAGUK family. I aimed to understand how overexpression of PSD-95 in
neurons of cultured hippocampal slices affects their synaptic currents. There were some
discrepancies in the data obtained by the different labs regarding the effect of PSD-95 on
synapse. I addressed the question of what accounts for these different observation and
performed some measurements under different experimental conditions. I further discussed
the caveats accompanying overexpression approach, suggesting that different protein levels,
onset and length of expression may alter the outcome of the experiments.
My study confirms that PSD-95 regulates trafficking of AMPA receptors in the synapse,
but also emphasizes on the effect of PSD-95 on synaptic NMDA receptor number, an effect
which was not observed in the previous studies or it was neglected. The significance of this
finding is the implication of PSD-95 as a general synaptic slot protein and a new view on
NMDA receptor dynamics in the synapse. I could also show that the effect of PSD-95 on
the synaptic currents is not mediated by changes in the presynaptic release probability but
that the locus of the PSD-95 effect is postsynaptic. In order to compare the effect of PSD-95
with other MAGUK family members, I overexpessed PSD-93 in hippocampal neurons and
observed much milder effect on the synaptic currents. This suggests that different MAGUKs
can serve differential role as scaffolds.
I examined the effect of PSD-95 on the rectification properties of synaptic AMPA recep-
tors and observed that PSD-95 overexpression led to an increased portion of GluR2-lacking
receptors. It is debated in the field whether GluR2-lacking receptors are present in the
CA1 neurons after the synapses are formed, and my work supports the findings that GluR2-
lacking receptors can be found in the synapse under certain conditions. It will be interesting
to further investigate what are the possible mechanisms underling this apparent selectivity
of PSD-95 for GluR2-lacking receptors.
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